Refine
Year of publication
Document Type
- Doctoral Thesis (127) (remove)
Language
- English (127) (remove)
Has Fulltext
- yes (127)
Is part of the Bibliography
- no (127)
Keywords
- Resistenz (3)
- Cytologie (2)
- Histologie (2)
- Immunchemie (2)
- Immunologie (2)
- Immunsystem (2)
- Inflammation (2)
- Kardiovaskuläre Krankheit (2)
- Leukozyt (2)
- Lymphozyt (2)
Institute
- Medizin (127) (remove)
Purpose: The aim of this work was to retrospectively identify prognostic factors for patients with neuroendocrine liver metastases (NELM) undergoing conventional transarterial chemoembolization (c-TACE), microwave ablation (MWA) or laser interstitial thermal therapy (LITT) and to determine the most effective therapy in terms of volume reduction and survival.
Method: Between 1996 and 2020, 130 patients (82 men, 48 women) were treated with c-TACE, 41 patients were additionally treated with thermoablative procedures.
Survival was retrospectively analyzed by using Kaplan-Meier-method. Prognostic factors were derived by using cox-regression. To find predictive factors for volume reduction due to c-TACE, a mixed-effects model was used.
Results: With c-TACE, an overall median volume reduction of 23.5 % was achieved. An average decrease of tumor volume was shown until the 6th c-TACE treatment, then the effect stopped. So, the median volume reduction off all lesions takes on a negative value from the 7th c-TACE intervention onwards. The mixed-effects model demonstrated that c-TACE interventions were most effective at the beginning of c-TACE therapy, and that treatment breaks longer than 90 days negatively influenced the outcome. For all patients evaluable for survival, Kaplan-Meier analysis showed a 1-year survival rate of 75 % and a 5-year survival rate of 36 %. Significant prognostic factors for survival were number of liver lesions (p = 0.0001) and therapeutical intention (p < 0.0001). Considering the clinical indication, 90.9 % of curative patients and 43.6 % of palliative patients responded to c-TACE therapy and thus could be submitted to a thermoablative procedure. Minor and one major complication occurred in 20.3 % of LITT and only in 8.6 % of MWA interventions. Complete ablation was observed in 95.7 % (LITT) and 93.1 % (MWA) of interventions
Conclusions: C-TACE is an effective treatment for volume reduction of NELM, however efficacy decreases after the 6th intervention and treatment breaks longer than 90 days should be avoided. With thermal ablation, a high rate of complete ablation was achieved and survival improved. Significant factors for survival were found and may be used as prognostic factors in the future.
Slack (sequence like a Ca2+ -activated K + channel; also termed Slo2.2, Kcnt1, or KNa 1.1) is a Na+ -activated K + channel that is highly expressed in the peripheral and central nervous system. Previous studies have shown that Slack is enriched in the isolectin B4binding, non-peptidergic subpopulation of C-fiber sensory neurons and that Slack controls the sensory input in neuropathic pain. Recent single-cell RNA-sequencing studies suggested that Slack is highly co-expressed with transient receptor potential (TRP) ankyrin 1 (TRPA1) in sensory neurons. By using in situ hybridization and immunostaining we confirmed that Slack is highly co-localized with TRPA1 in sensory neurons, but only to a minor extent with TRP vanilloid 1. Mice lacking Slack globally or conditionally in sensory neurons (SNS-Slack─/─ ), but not mice lacking Slack conditionally in neurons of the spinal dorsal horn (Lbx1-Slack─/─ ), displayed increased pain behavior after intraplantar injection of the TRPA1 activator allyl isothiocyanate. Patch-clamp recordings with cultured primary neurons and in a HEK-293 cell line transfected with TRPA1 and Slack revealed that Slack-dependent K + currents are modulated in a TRPA1-dependent manner. Taken together, these findings highlight Slack as a modulator of TRPA1-mediated activation of sensory neurons.
Furthermore, we investigated the contribution of Slack in the spinal dorsal horn to pain processing. Lbx1-Slack ─/─ mice demonstrated normal basal pain sensitivity and Complete Freund’s Adjuvant-induced inflammatory pain. Interestingly, we observed a significantly increased spared nerve injury (SNI)-induced neuropathic pain hypersensitivity in Lbx1-Slack ─/─ mutants compared to control littermates. Moreover, we tested the effects of pharmacological Slack activation in the SNI model. Systemic and intrathecal, but not intraplantar administration of the Slack opener loxapine significantly alleviated SNI-induced hypersensitivity in control mice, but only slightly in Lbx1Slack ─/─ mice, further supporting the inhibitory function of Slack in spinal dorsal horn neurons in neuropathic pain processing.
Altogether, our data suggest that Slack in sensory neurons controls TRPA1-induced pain, whereas Slack in spinal dorsal horn neurons inhibits peripheral nerve injury induced neuropathic pain. These data provide further insights into the molecular mechanisms of pain sensation.
The visual system encompasses about 20% of the cerebral cortex1 and plays a pivotal role in higher-order cognitive processes such as attention and working memory. Cognitive impairments constitute a central role in neuropsychiatric disorders such as schizophrenia (SZ). Impairments are described in visual perceptual processes including contrast, and emotion discrimination as well as in the ability to identify visual irregularities and in higher-order cognition like visual attention and working memory. Furthermore, perceptual and higher-order cognitive processes are part of the Research Domain Criteria (RDoC) project that aims to develop dimensional and transdiagnostic constructs with defined links to specific brain circuits.Therefore, the detailed study of the visual system using functional magnetic resonance imaging (fMRI) is essential to understand the processes in healthy individuals but also in populations with neuropsychiatric disorders. Visual mapping techniques include functional localizer tasks to map functionally defined regions like the fusiform face area (FFA), retinotopic mapping to map specific brain regions that are retinotopically organized in full, and visual-field localizer paradigms to define circumscribed areas within retinotopically organized areas.Thus, the latter allow studying local information processing in early visual areas. Despite advances in neuroimaging techniques, analyses of fMRI data at the group-level are impeded by interindividual macroanatomical variability. This reduces the reliability to accurately define visual areas particularly at the group-level and decreases statistical power. Single-subject based solutions for this problem are not appropriate. Analyses after volume-based alignment (VBA) and primary surface-based analyses without macroanatomical alignment do not increase macroanatomical correspondence sufficiently. Cortex-based alignment (CBA) approaches are recommended as an alternative technique to address this obstacle. However, CBA has not been evaluated for visual-field localizer paradigms. Therefore, we aimed to evaluate potential benefits of CBA for an attention-enhanced visual field localizer paradigm that maps circumscribed regions in retinotopically organized visual areas. Since previous studies solely compared surface-based data before and after CBA, we aimed to compare all three techniques: (1) a volume-based alignment (VBA), (2) a surface-based data set without (SBAV) and (3) a surface- based data set with macroanatomical alignment (CBA). Furthermore, we sought to define regions of interest (ROI) that subsequently can be used for the study of higher-order cognitive processes. Also, we aimed to investigate whether CBA facilitates the study of functional asymmetries in early visual areas as these were described in previous studies. Healthy volunteers (n=50) underwent fMRI in a 3- Tesla Siemens Trio scanner while performing an attention-enhanced visual field localizer paradigm. Our task consisted of a series of flickering, black-and white colored checkerboard stimuli that randomly appeared at one of four locations comprising the participants’ visual quadrants. In 25% of the trials the centrally located squares briefly changed their color to yellow (target trial). Participants had to indicate detection of a target by button press. Data analysis was conducted using Brain Voyager 20.6. Our approach for macroanatomical alignment included a high-resolution, multiscale curvature driven alignment procedure minimizing interindividual macroanatomical variability. Here, each folding pattern was aligned to a dynamically updated group average. Thus, we counteracted a possible confounding effect of a suboptimal selection of an individual target brain with a folding pattern deviating considerably from the cohort average. Group ROIs after CBA showed increased spatial consistency, vertical symmetry, and an increase of size. This was corroborated by an increase in the probability of activation overlap of up to 86%. CBA increased macroanatomical correspondence and thus ameliorated results of multi-subject ROI analyses. Functional differences in the form of a downward bias in visual hemifields were measured with increased reliability. In summary, our findings provide clear evidence for the superiority of CBA for the study of local information processing in early visual cortex at the group-level. This approach is of relevance for the study of visual dysfunction in neuropsychiatric disorders including schizophrenia as they show impaired visual processing that in turn impacts higher-order cognitive processes and in consequence functional outcome. In addition, our attention-enhanced visual field localizer paradigm will be useful for machine learning approaches such as multivariate pattern analysis decoding local information processes and connectivity patterns.
Cardiovascular disease (CVD) is the leading cause of death in the western world. Aging as the major risk factor for the development of CVD leads to structural changes in the heart and the vasculature. In addition to endothelial cells, mural cells, including smooth muscle cells and pericytes, form the vascular wall. Pericytes are defined as the perivascular cells located in the basement membrane of the capillaries, which are the smallest components of the vascular system and ensure the gas exchange in the tissue. In the different parts of the terminal vascular bed, pericytes receive different phenotypes and organ-specific functions. In addition to the stabilization of the vascular wall, pericytes are relevant for the formation of new vessels. Due to their potential of multipotent stem cells, pericytes can differentiate into different cell types and thus take a position in developmental processes. Pericytes play a crucial role in the development and diseases of the vascular system. Moreover, pericyte coverage is reduced in the aged heart. Nonetheless, the function of pericytes in the heart and their importance during cardiac aging is not completely understood.
To study the pericyte population in the aging heart, we have performed single-nucleus RNA-sequencing analysis comparing hearts from 12-weeks-old (young) and 18-month-old (old) mice. The detailed analysis of 336 differentially expressed genes (DEG) revealed that Rgs5 is downregulated in aged pericytes. Regulator of G-protein signaling 5 (RGS5), an established marker for pericytes, is involved the regulation of the blood pressure and in the formation of various cardiovascular diesases, including cardiac hypertrophy, myocardial infarction and atherosclerosis. We have furthermore confirmed this observation in vivo. Gene ontology (GO) analysis of DEG revealed that aged pericytes are characterized by the downregulation of genes involved in cell adhesion. Further, we have performed cell biology approaches using human brain vascular pericytes (hBVP) to investigate the role of Rgs5 in pericytes in vitro. Efficient knockdown of RGS5, although has no effect on cellular metabolism, viability and endothelial permeability, induces a reduction of pericyte adhesion to both a gelatine matrix and endothelial cells in a 3D matrigel culture. This was associated with the formation of filopodia. The altered phenotype suggested a changing identity of the pericytes. We could confirm that a loss of RGS5 causes a decreased expression of the pericyte markers PDGFRb and NOTCH3 and also leads to an overexpression of COL1A1, a fibroblast marker.
Together, our findings suggest that RGS5 is required for pericyte adhesion to endothelial cells and its downregulation in the aged mural cells could explain the reduction of pericyte coverage in the aged hearts. Further, RGS5 may be the key regulator for pericyte identity, as pericytes show an altered expression profile of cellular markers. The dedifferentiation of pericytes to a more fibroblast-like cell type could explain the increased fibrosis during age-related cardiac remodeling. We believe that RGS5 is a great candidate to explore and study the molecular mechanisms that regulate pericyte function in the heart, both in homeostasis and during aging.
Many countries have restricted public life during the SARS-CoV2 pandemic. As related measures limited the access to sports facilities, this dissertation aimed (1) to examine changes in physical activity (PA) and well-being in affected countries, and (2) to determine the effectiveness of a digital home exercise program in this context.
Part 1 (PA/well-being) of the dissertation was a digital survey administered in 14 countries. Participants reported a 41 - 42% reduction of PA (NPAQ-SF) during restrictions (n=13,503 valid responses). Compliance with international PA guidelines decreased by nearly 19%. Mental well-being declined substantially (n=14,975 responses; 68.1 to 51.9 points on the WHO5 index) and the proportion of individuals at risk of depression tripled (14.2% to 45.2%). Physical well-being (SF-36 Pain) decreased slightly (85.8% to 81.3%). About two thirds (68.1%) of the respondents reported being interested in digital home exercise.
For Part 2 (digital home exercise) of the dissertation, an international multicenter randomized, controlled trial was performed allocating healthy adults (n=763; 33±12 years) to an intervention (IG) or control (CG) group. In contrast to the CG, the IG was offered live-streamed home exercise for four weeks. Subsequently, both groups had access to pre-recorded workouts for another four weeks. Outcomes were measured weekly using validated questionnaires. Mixed-models data analyses revealed an up to 1.65-fold (95% CI: 1.4-1.94; week 1) increase of PA relative to the CG. Moreover, small improvements in exercise motivation (SKK scale), psychological well-being (WHO-5 index), sleep quality (MOS Sleep Scale), and anxiety symptoms (GAD-7 Scale) were observed for IG.
The results of this dissertation suggest that public life restrictions associated with the pandemic had significant adverse effects on movement behavior and well-being. Digital home exercise can help to maintain and/or increase health- beneficial PA and well-being and may hence represent a supportive element of viral containment efforts.
Characteristics of critical incident reporting systems in primary care: an international survey
(2022)
Aim: The aim of the study was to support the development of future critical incident reporting systems (CIRS) in primary care by collecting information on existing systems. Our focus was on processes used to report and analyse incidents, as well as strategies used to overcome difficulties.
Methods: Based on literature from throughout the world, we identified existing CIRS in primary care. We developed a questionnaire and sent it to operators of a purposeful sample of 17 CIRS in primary care. We used cross-case analysis to compare the answers and pinpoint important similarities and differences in the CIRS in our sample.
Results: Ten CIRS operators filled out the questionnaire, and 9 systems met the inclusion criteria. The sample of CIRS came from 8 different countries and was rather heterogeneous. The reporting systems invited a broad range of professions to report, with some also including reports by patients. In most cases, reporting was voluntary and conducted via an online reporting form. Reports were analysed locally, centrally, or both. The various CIRS used interesting ideas to deal with barriers. Some, for example, used confidential reporting modes as a compromise between anonymity and the need for follow-up investigations, whereas others used smartphone applications and call centres to speed up the reporting process.
Conclusion: We found multiple CIRS that have operated in primary care for many years, have received a high number of reports and were largely developed in accordance with recommendations found in literature. Although primary care in Germany differs from other countries, these CIRS could serve as an inspiration for CIRS in German primary care.
Background: During ECMO therapy ischemia of the limbs or internal organs are potential lethal complications. This study analyzed incidence and type of ischemic complications during ECMO therapy, divided in limb, mesenteric, cardiac and neurological ischemia.
Methods: In this single-center retrospective observational study data from 348 patients treated with veno-venous, veno-arterial or veno-venous-arterial ECMO at the Asklepios Klinik Langen between April 1st 2011 and March 31st 2020 was screened. 321 patients with diagnosis of acute respiratory distress syndrome, cardiogenic or septic shock were included.
Primary outcome variable was type of ischemic complication. Further variables were serum lactate levels 24h before and immediately after diagnosis of the ischemic complication, duration of ICU and hospital stay, ECMO therapy and duration of invasive ventilation and arterial blood gas analysis on day of admission to the ICU. Age, sex, ECMO mode, diagnosis, SAPS II, SOFA score, hospital mortality, the use of renal replacement therapy and tracheotomy, the occurrence of infections during the ICU stay and the need of CPR before ECMO implantation were recorded as well.
Results: 62/321 patients (19.3%) were diagnosed with an ischemic complication. Most common areas were limbs (n=32) and mesenteric ischemia (n=21). Patients who were diagnosed with a septic shock had the highest rate of ischemic complications (36.2%). In VV mode there was a difference in survival between patients with and without ischemic complication (p=0.025). Using multivariate logistic regression, age ≥50 years (p=0.029; OR=2.793; CI 1.109 – 7.033), use of hemodialysis (p=0.003; OR=3.283; CI=1.513 – 7.124) and initial diagnosis of a septic shock (p=0.049; OR=2.144; CI=1.003 – 4.583) could be identified as predictors for ischemic complications.
Conclusions: Ischemic complications are frequent during ECMO therapy. An age of at least 50 years, the use of hemodialysis and diagnosis of a septic shock were predictors of ischemic complications. No correlation between ECMO mode and ischemic complications was found. An influence of ischemic complications on survival could be found only in patients treated with VV mode.
Background: Increasing numbers of patients surviving malignant bone tumors around the knee joint have led to an increasing importance to investigate long-term results. This study assessed the long-term results of rotationplasty after resection of malignant bone tumors regarding functional outcome and quality of life to allow better comparison with other treatment options in bone cancer treatment.
Procedure: 60 participants who underwent rotationplasty due to bone cancer took part in this multicentric questionnaire- based study. The long-term functional outcome was measured by the Musculoskeletal tumor society score (MSTS) and the Tegner activity level scale. The health-related quality of life (HRQL) was assessed by using the Short Form Health Survey (SF-36).
Results: Patients treated with rotationplasty (median follow- up of 22 years, range 10–47 years) regained a high level of activity (median MSTS score of 24). Even a return to high level sports was possible (mean Tegner activity level scale of 4). Duration of follow-up did not influence the functional outcome. HRQL scores were comparable to the general German popula tion. Concerns of psychological problems due to the unusual appearance of the rotated foot have not been confirmed.
Conclusion: Rotationplasty can be a good alternative to en- doprosthetic replacement or amputation, either as primary surgery or as a salvage procedure. Especially for growing children and very active patients rotationplasty should be considered.
Acute myeloid leukemia (AML) is a neoplastic disease of an early myeloid precursor cell in hematopoiesis. It leads to the accumulation of monoclonal cells in the bone marrow and the peripheral blood, showing a differentiation block and deregulated self-renewal. Frequently, the leukemic cells exhibit genetic aberrations with reciprocal chromosomal translocations. These translocations induce the formation of a fusion protein, that can lead to new cellular functions and a transformation into a leukemic cell. Common chromosomal translocation in AML are t(8;21) or t(15;17), which cause the formation of the fusion proteins AML1/ETO and PML/RARα and determine the leukemic phenotype of the AML.
The translocation t(6;9) leads to the formation of the fusion protein DEK/CAN and is of special interest, because of its association with mostly young patients and a very aggressive course of the disease. The fusion product induces leukemia in a small subset of hematopoietic stem cells, but its mechanism of leukemogenesis is greatly unknown.
The intention of this work was to characterize the DEK/CAN-induced AML on a molecular genetic level to gain a deeper understanding of the disease pathogenesis. Therefore, gene expression analysis with polymerase chain reaction (PCR) and microarray analysis was performed.
To detect DEK/CAN in different cell lines by PCR and real-time quantitative PCR (qPCR), specific primers and probes were designed, and a standardized workflow was established. Emphasis was placed on the optimization of RNA isolation, DNase treatment, cDNA synthesis with following PCR and qPCR, which enabled the detection of the fusion product DEK/CAN in the cell lines 32B, Phoenix and FKH-1. To quantify the fusion product DEK/CAN, the method of qPCR with absolute and relative quantification was used. Absolute quantification enabled the calculation of an exact copy number of the fusion transcript DEK/CAN with a detection limit of 50 copies/µl at a sensitivity of 10-6, which is of importance in determining the minimal residual disease (MRD) of patients with DEK/CAN-positive AML. MRD detection by qPCR is a highly sensitive diagnostic method to identify leukemic cells, even in low cell counts. This enables a thorough evaluation of the treatment response and allows an early detection of changes in the MRD level as part of the remission control.
Additionally, a microarray gene expression analysis was performed to identify alterations in relevant target genes and associated signaling pathways in DEK/CAN-positive cells.
Because of DEK/CAN’s potential to induce leukemia in a subset of hematopoietic stem cells, Sca+/Lin- cells of the bone marrow of C57Bl/6 mice were used and transfected with the gene products DEK/CAN and PML/RARα. Microarray analysis led to the identification of 16 different genes of interest, which demonstrated significant alterations of gene expression in DEK/CAN-positive cells. They were validated and quantified with TaqMan assay assisted qPCR. The elevated expression of the transcription factors TRIM25, HIF1α and ATF2, in DEK/CAN-positive cells, indicated an altered transcription factor activity and interaction with DNA in the nucleus. The localization of DEK/CAN in the nucleus emphasizes this assumption. Also, the upregulated expression of the nuclear export receptor XPO1 suggested changes in nuclear transport processes and impaired export activity in DEK/CAN-positive cells.
Furthermore, the results demonstrated changes of gene expression in genes that are involved in the JAK/STAT signaling pathway. PTPRC, the Protein Tyrosine Phosphatase Receptor Type C, functions as a direct inhibitor of JAKs (Janus Kinases) and STATs (Signal Transducers and Activators of Transcription) and their associated signaling pathway.
It was shown that the gene expression of PTPRC was significantly reduced in DEK/CAN-positive cells. This allowed the assumption, that the reduced expression of PTPRC led to a loss of inhibition and thus a consecutive hyperactivation of the JAK/STAT signaling pathway. This hypothesis was supported by an independent activation of PIM1, a target gene of STAT5 and the activation of LMO2, a direct target gene of JAK2. In addition, the transmembrane receptor CSF1R, which is directly involved in STAT activation, also showed an upregulation in gene expression.
The results of this work show an activation of the JAK/STAT signaling pathway in DEK/CAN-positive cells, which may be a key mechanism in DEK/CAN-induced leukemogenesis.
Considering treatment options in the future, the addition of targeted therapy, such as pan-JAK inhibitors, to the standard therapy, could be a chance to improve the overall survival rate and the prognosis of t(6;9)-positive AML.
Gait analysis as a clinical examination method has been increasingly used in recent years. In particular, the external knee adduction moment was often used as a surrogate measure for internal medial knee joint loading, e.g., in elderly individuals with medial knee osteoarthritis. Therefore, the knee adduction moment is also associated with the progression of knee osteoarthritis. Children and adolescents with valgus malalignment have been found to experience a reduced external knee adduction moment, but internal knee joint contact forces, particularly in the lateral compartment, were not previously studied.
First, medial and lateral knee joint contact forces were studied using muskulosceletal modeling in young individuals with and without valgus malalignment treated by guided growth. In addition, a systematic literature review was conducted to explore the relationship between external joint moments and internal joint contact forces. Finally, this relationship was investigated in children and adolescents with and without valgus malalignment. Furthermore, we examined whether statistical models could be determined to accurately predict internal knee joint contact forces by commonly used parameters from three-dimensional gait analysis, such as external knee joint moments.
It was found that guided growth normalized knee joint contact forces after treatment. In addition, the static radiographic mechanical axis angle correlated better after the treatment when the patients showed a typical limb alignment compared to the correlation before guided growth with the valgus malalignment due to compensating strategies during gait. Furthermore, the systematic review showed that the peak medial knee joint contact force was best predicted by the knee adduction moment and even better together with the knee flexion moment in the first half of stance. However, for the second half of stance of the medial knee joint contact force and the entire stance of the lateral knee joint contact force, only low correlations with knee adduction and/or flexion moment were found. Finally, statistical models could be determined with high accuracy for both medial and lateral knee joint contact force, for both peaks in the first and second half of stance, and for both study groups of children and adolescents with and without valgus malalignment by including knee adduction and flexion moment as predictors.
These results demonstrate the importance of examining not only the external knee adduction moment but also the knee flexion moment and, even better, the medial and lateral knee joint contact forces when evaluating knee joint loading. With these statistical models, clinicians can predict the medial and lateral knee joint contact forces without the need to perform musculoskeletal simulations and can therefore use standard three-dimensional gait analysis parameters such as knee adduction and flexion moment. This can improve guided growth treatment in children and adolescents with valgus malalignment with regard to implantation or explantation of the growth restricting plates or to rebound. Instrumented gait analysis could be particularly helpful in borderline cases, as kinematic compensation mechanisms during gait may play a role and the static radiograph alone does not provide information about dynamic joint loads.
Aortic valve (AV) and root replacement with composite graft and re-implantation of coronary arteries described first by Bentall and de Bono in 1968, is considered as a standard operation for treatment of different pathologies of the AV and aortic root. In centres where aortic valve and root repair techniques and Ross operation are well established, generally severely diseased patients remain indicated for this procedure. The aim of this study was to evaluate the early and long-term outcomes after Bentall-De Bono (BD) procedures in high-risk population with complex pathologies and multiple comorbidities.
Between 2005 and 2018, a total of 273 consecutive patients (median age 66 years; 23 % female) underwent AV and root replacement with composite-graft in so called button technique. We divided our population in the following groups: 1. acute type A aortic dissection group (ATAAD) (n = 48), 2. endocarditis group (n = 99) and 3. all other pathologies group (n = 126). The surgery has been per- formed emergent/urgent in 131 patients (49 %) and in 109 cases (40%) as a reoperation. Concomitant surgery was required in 97 patients (58%) and 167 pa- tients (61%) received a biological composite-graft.
Follow-up was completed in 96% (10 patients lost to follow-up) with a mean of 8.6 years (range 0.1-15.7 years), counting a total of 1450 patient-years. Thirty- day mortality was 17% (46 patients). The overall estimated survival in 5 and 10 years was 64% ± 3%) and 46% ±4 %). Group comparison showed a significant difference in favour of patient from the dissection group (p = 0.008). Implantation of a biological valve graft was associated with lower survival probability (p < 0.001). There was no significant difference in the freedom of reoperation rate between the groups. The same applies for freedom of postoperative endocarditis, thromboembolic events, and aortic prosthesis dysfunction. According to the uni- variate and multivariate logistic regression analysis primarily postoperative neu- rological dysfunction (OR 5.45), hypertension (OR 4.8) peripheral artery disease (OR 4.4), re-exploration for bleeding (OR 3.37) and postoperative renal replace- ment therapy (OR 3.09) were identified as leading predictors of mortality.
In conclusion, the BD operation can be performed with acceptable short- and long-term results in high-risk patients with complex aortic pathologies in a centre with well-established AV repair and Ross operation program.
While B-cell acute lymphoblastic leukaemia (B-ALL) can be described as the leukaemia of childhood, chronic myeloid leukaemia (CML) mostly develops in elderly individuals. Understanding and utilising mechanisms involved in the development and persistence of these leukaemias as possible targets for treatment strategies has received particular interest. Processes that happen in the vicinity of the cancerous cells themselves could influence cancer growth and behaviour and hence can serve as novel targets, leading to the development of two-pronged therapies that act both on leukaemic cells directly as well as their niche. The niche in the case of leukaemia is the bone marrow microenvironment (BMM) where these cells are not only generated but also instructed and protected. As the BMM is situated inside bones that undergo drastic changes and growth processes during the ageing process, the BMM itself is also being altered throughout life. These alterations and the very process of expansion itself may therefore also provide distinct regulatory influences on the cells (healthy or malignant) that are generated inside this niche, leading to the question: Does the age of the bone marrow microenvironment differentially influence the development of (“childhood”) B-ALL versus (“adult”) CML by the release of cytokines?
In previous studies by the host-laboratory the age distribution of B-ALL versus CML in a murine transduction/ transplantation model could be recapitulated; young mice which received the same number of leukaemia-initiating cells as their old counterparts died significantly earlier of B-ALL while showing a significantly delayed clinical course, when they were suffering from CML. The tumour load and other leukaemia-associated parameters also showed a clear disposition towards preferential induction of CML in elderly and B-ALL in younger mice.
In this project we could support the hypothesis that the age of the BMM differentially influences the proliferation of leukaemic cells and thereby the development and persistence of different types of leukaemias by utilising different in vitro culture experiments. Specifically, we could show that young (compared to old) bone marrow
11 stroma cells (BMSC) support the growth of (BCR-ABL1+) B-ALL cells both in a direct, cell on cell co-culture setting, as well as in young BMSC-derived conditioned medium. This supports the hypothesis that varying factors are differentially released from a young versus an old BMM and influence the growth of the leukaemia cells. The opposite might be true for CML cells (BCR-ABL1+ 32D cells); BMSC obtained from old animals showed a tendency to support their growth more profoundly than cells acquired from young animals.
Possible proteins responsible for the distinct regulation of myeloid versus lymphatic leukaemic cells by young versus old BMM have also been studied. We investigated C-X-C motif chemokine 13 (CXCL13) and growth differentiation factor 11 (GDF11) in their effect on leukaemia cells, as both proteins having previously been described to have tumour-modelling properties and age-dependent levels (see below).
We identified an increased secretion of CXCL13, a B-cell chemotactic factor, into conditioned medium from young versus old BMSC. In accordance with this we found migration of B-ALL cells towards BMSC from young compared to old mice to be improved, while adhesion of both B-ALL and CML cells to young versus old BMSC did not show any differences. By blocking CXCL13 the proliferation-supporting effect of young BMSC on B-ALL cells could be diminished. Similar effects could be demonstrated by blocking GDF11.
In the case of CML cells we could observe the opposite effect; blocking CXCL13 and GDF11 increased their proliferation in a co-culture with BMSC. This supported our hypothesis that both cytokines differentially regulate B-ALL and CML behaviour. After the completion of this thesis, another member of the host-laboratory convincingly demonstrated the role of BMM age in the regulation of B-ALL via CXCL13 signalling (see discussion).
In haploidentical stem cell transplantation (SCT), achieving a balance between graft versus host disease (GvHD), graft versus leukemia effect (GvL) and bridging the vulnerable phase of aplasia against viral infections is still a challenge. Graft preparation strategies attempt to achieve this balance by removing and retaining harmful and helpful cells. At this point it is known that T cell subpopulations hold different properties concerning GvHD promotion and immunocompetence towards pathogens. CD45RA+ naïve T cells show the greatest, while CD45RO+ memory T cells show less alloreactive potential but provide immunocompetence. CD45RA depletion is a promising new approach to graft processing that potentially combines GvHD prevention, GvL promotion and transfer of immunological competence by removing potentially harmful CD45RA+ naïve T cells and retaining CD45RO+ memory cells. This work focused on manufacturing CD45RA-depleted grafts within a one- or two-step approach, as well as a feasibility assessment of the process and the establishment of a 10-color fluorescence activated cell sorting (FACS) measurement panel for clinical-scale graft generation. CD45RA depletions were conducted from granulocyte-colony stimulated factor (G-CSF) mobilized peripheral blood stem cells (PBSC) applying two different strategies, direct depletion of CD45RA+ cells (one-step approach), or depletion following preceding CD34 selection. A 10-color FACS measurement panel was established ensuring quality control and enabling preliminary data acquisition on CD45RA co-expression for cell loss estimations. Residual virus-specific T cells after depletion were measured using MHC multimers. It was observed that the depletion antibody occupied the cell binding sites, resulting in insufficient binding of the fluorescent dye for subsequent FACS measurement. Therefore, three FACS antibodies were tested and compared, and CD45RA-PE (clone:2H4) was found to be the best choice for reliable cell detection. To further characterize residual T cells, two homing markers, CD62L and CCR7, were compared, with particular attention paid to the expression of the surface markers after cooling. Both markers were complementary to each other, resulting in the decision to include an additional FACS measuring tube whenever samples are cooled or further T cell characterization is needed. With a median log depletion of -3.9 (one-step) and -3.8 (two-step) data showed equally efficient removal of CD45RA+CD3+ T cells for both approaches. Close to complete B cell removal was obtained without additional reagent use. However, also close to complete NK cell loss occurred due to high CD45RA co-expression. Stem cells recovered at a median of 52% (range: 49.7 - 67.2%) after one-step CD45RA depletion. CD45RO+ memory T cells recovery was statistically not differing between both approaches. Virus-specific T cells were detectable after depletion, suggesting that virus-specific immunocompetence is transferable. In conclusion, CD45RA depletions are equally feasible for both approaches when performed from fresh, non-cryopreserved starting products, show reliable reduction of CD45RA and B cells, but also result in co-depletion of NK cells. Stem cell recovery and NK cell losses must be considered carefully especially regarding overcoming HLA barriers, pathogen protection during aplasia, early engraftment an GvL. Therefore, a combination of CD45RA-depleted products with already established other processing methods to ensure sufficient stem and NK cells is desirable to allow high clinical flexibility.
Despite major improvements of the therapy, many B-cell Non-Hodgkin’s lymphoma (B-NHL) entities still have a poor prognosis. New therapeutic options are urgently needed. Therefore this study sets out to investigate oncogenic signalling pathways in the two B-NHL entities mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) in order to define new potential therapeutic targets.
MCL cells overexpress the anti-apoptotic protein BCL-2, thereby they evade apoptosis. With venetoclax, the first-in-class BCL-2 specific inhibitor was approved and achieved good response rates in MCL. However, some cases display intrinsic or acquired resistance to venetoclax. In order to improve the therapy, this study aimed to identify genes which confer sensitivity or resistance towards venetoclax upon their respective knockout. To this end, a genome-wide CRISPR/Cas9-based loss-of-function screen was conducted in the MCL cell line Maver-1. The E3 ubiquitin
ligase MARCH5 was identified as one of the top hits conferring sensitivity
towards venetoclax upon its knockout. This finding was validated in a competitive growth assay including two more MCL cell lines, Jeko-1 and Mino. MARCH5 knockout also sensitised Jeko-1 cells towards venetoclax even though this cell line was insensitive towards venetoclax in its wild-type form. Using BH3 profiling, an increased dependency on BCL-2 of MARCH5-depleted cells confirmed this finding. The sensitisation was found to be based on induction of apoptosis upon MARCH5 knockout and to an even higher extent upon additional treatment of MARCH5-depleted cells with venetoclax. As already described for epithelial cancer entities, the BCL-2 family members MCL-1 and NOXA were upregulated in MCL cell lines upon MARCH5 knockout. This led to the hypothesis that MARCH5 is a potential
regulator of intrinsic apoptosis with NOXA as a key component. A competitive growth assay with MARCH5 and NOXA co-depleted cells revealed a partial reversion of the BCL-2 sensitisation compared to MARCH5 knockout alone. Furthermore, mass spectrometry-based methods were used to gain more insight into other cellular pathways and networks which might be regulated in a MARCH5-dependent manner. In an interactome analysis, proteins which regulate mitochondrial morphology, such as Drp-1 were identified as MARCH5 interactors. Besides this expected finding, interaction between MARCH5 and several members of the BCL-2 family as well as a potential connection between MARCH5 and vesicular trafficking was discovered. As expected, an ubiquitinome analysis of MARCH5-depleted cells revealed decreased levels of MCL-1 and NOXA ubiquitination. Additionally, a potential role of MARCH5 in the ubiquitination of several members of the cell cycle regulatory
pathway was discovered. Based on the broad spectrum of cellular pathways which seem to be regulated in a MARCH5-dependent manner, it was hypothesised that MARCH5 primarily regulates BCL-2 family members which in turn regulate intrinsic apoptosis on the one hand and additionally are involved in the regulation of various other pathways on the other hand.
In summary, this study provides insight into a MARCH5-dependent MCL1-1/NOXA axis in MCL cells and potential implications into related cellular processes.
In addition to the anti-apoptotic pathways described above, B-cell receptor (BCR) signalling is known to provide a pro-survival signal to both normal and malignant B-cells. Targeting the BCR signalling pathway therefore is a promising therapeutic target for B-cell malignancies. In order to gain more insight into the differential modes of BCR signalling of ABC- and GCB-DLBCL cells, genes/proteins which displayed differential essentiality in ABC- and GCB-DLBCL cells were aimed to be defined. Consequently, data sets from a CRISPR/Cas9-based loss-of-function screen
were re-analysed. SASH3 was identified as a gene which was essential for GCB- but not for ABC-DLBCL cells. Since this protein is known to be involved in T-cell receptor (TCR)-signalling, SASH3 was assumed to play a potential role in BCR signalling as well and was therefore investigated in more detail. A competitive growth assay confirmed that SASH3 knockout was toxic exclusively for GCB-DLBCL cell lines. An interactome analysis in ABC- and GCB-DLBCL cells revealed interaction between SASH3 and many components of the proximal BCR signalling pathway as well as several downstream signalling pathways such as the PI3K or the NF-ΚB pathway.
An integration of the interactome with data from the CRISPR/Cas9-based loss-offunction screen revealed differential essentiality of the SASH3-interacting proteins in ABC- and GCB-DLBCL cells. It was hypothesised that SASH3 might regulate PI3K signalling on which GCB- but not ABC-DLBCL cells are known to dependent. Discontinuation of the regulation of PI3K signalling could therefore be exclusively toxic to GCB-DLBCL cells.
Taken together, this study describes a subtype-specific dependency of GCB-DLBCL cells on SASH3. Furthermore, the SASH3 interactome has been investigated in B-cells for the first time, thereby highlighting a potential role in proximal BCR signalling and involvement in specific BCR-related downstream signalling pathways.
The postthrombotic syndrome (PTS) is beside the venous thromboembolism (VTE) recurrence and chronic thromboembolic pulmonary hypertension (CTEPH) a long-term adverse outcome and chronic complication of deep vein thrombosis (DVT) in the lower extremities and can occur in up to 20–50% of patients within 2 years after DVT. The prevalence of PTS in the adult population is expected to increase due to the growing incidence of VTE in the elderly. Although not life threatening it can impose significant morbidity and can be associated with a negative impact on quality of life associated with disease severity. From an economic point of view, PTS is an important predictor of increased health care costs after VTE.
Factors potentially related to the development of the PTS are older age, obesity, a history of previous ipsilateral DVT, iliofemoral location of the current thrombosis, failure to promptly recover from the acute symptoms and insufficient quality of oral anticoagulant therapy. Furthermore, it is known that the severity of PTS correlates with the location of the DVT, the more proximal the more severe.
PTS induces a range of symptoms and clinical signs, which can be assessed in different scales. The Villalta scale is one of the most suitable scales for defining the presence and severity of subjective symptoms and physical signs of PTS.
In the last century, various therapeutic strategies have been developed to prevent mortality due to VTE or long-term morbidity due to PTS.
Conservative treatment today consists of anticoagulation - usually using direct oral anticoagulants - and compression therapy. One of the first invasive treatments with the aim of thrombus removal was surgical venous thrombectomy by Läwen in 1938. Mahorner and Fontaine improved the technique in the 1950s combining it with a course of anticoagulant treatment to prevent rethrombosis and PTS.
Mechanical thrombectomy by the use of Fogarty balloons, which started in 1963, or the creation of a transient arteriovenous fistula, performed since 1974, are now no longer recommended due to the high invasiveness, risk of fatal intraoperative embolism and a high rethrombosis rate.
In current practice, early thrombus removal mainly relies on the use of catheter-directed pharmacologic thrombolytic therapy. Another approach currently is the endovenous, device-driven thrombectomy and stenting in case of venous obstruction. There is an ongoing broad discussion as to whether these invasive therapies should be offered to patients with iliofemoral thrombosis (IFT), which remains controversial.
IFT, the major target for endovenous thrombectomy respectively pharmacologic thrombolytic therapy, is not enough represented in current literature because the used definition of proximal DVT does not necessarily include the iliac veins. In consequence, it may not be representative enough concerning questions like prevalence and severity of PTS or the effects on quality of life.
The present registry – the Iliaca-PTS registry – addresses exactly these patients and tries to answer these questions. The data of 85 patients who had suffered an IFT in the past were evaluated in the prospective registry documenting the severity of PTS, the occurrence of iliac vein compression syndrome in left-sided IFT and quality of life. A significant predictor for the development of severe PTS or venous claudication in our patient population is a high BMI.
The results of this registry show that IFT is frequently observed and only ten percent develop a moderate or severe PTS respectively venous claudication. In conclusion, the conservative treatment strategy with optimal effective anticoagulant therapy can lead to a low incidence of PTS and a high quality of life.
Treatment response to neoadjuvant chemoradiotherapy (nCRT) varies considerably among individual patients in advanced rectal cancer indicating a clinical need for markers to predict treatment efficacy and to stratify patients for future personalized treatment. In recent years, there is a tremendous evidence on a pivotal impact of immune components on the development/pathogenesis of cancer and on mediating response to radiation and chemotherapy. Moreover, liquid biopsy biomarkers have become increasingly attractive to predict treatment response because they are easy to collect, reflect information on different aspects of tumor biology and can be accurately measured by standardized methods.
This study aimed to investigate the peripheral blood and tumor tissue immune cell contexture in patients with rectal adenocarcinoma treated with nCRT and chemotherapy (CT) within a prospective randomized phase II CAO-ARO-AIO-12 trial, conducted in the context of DKTK (Deutsches Konsortium für translationale Krebsforschung) and FCI (Frankfurt Cancer Institute), to address the questions whether peripheral blood and/or primary tumor immune contexture predict for treatment response, were modulated by nCRT/CT and correlated with each other. By this, immune cell components were assayed by flow cytometry from peripheral blood mononuclear cells (PBMCs) at baseline, day 43, and pre-surgery of 22 patients treated with nCRT/CT and subsequently correlated with pathologic treatment response. Immunophenotyping was performed applying different staining panels covering myeloid immune cells and human leukocyte antigen (HLA) molecules, T lymphocyte subpopulations and programmed cell death (PD)-1 protein expression and regulatory T cells (Tregs). In addition, tumor tissue samples from pre-therapeutic biopsies and surgical specimens were analyzed by immunohistochemistry and multiparametric immunofluorescence.
The present prospective study raised the following issues. First, peripheral lymphocytes seem to play a crucial role in the nCRT/CT mediated systemic anticancer immunological response. Second, among the various lymphocyte subsets, peripheral blood, but not tissue resident T lymphocytes seem to play a central role in predicting treatment response. By this, baseline blood phenotyping revealed a lymphocyte distribution with high numbers of (CD3+CD4+) T helper cells and low numbers of (CD3+CD8+) cytotoxic T cells expressing PD1, activation markers GranzymeB, perforin and HLA-DR to be associated with an improved response (ypT0ypN0) to nCRT/CT in the patient’s cohort investigated. Further, a decrease in B lymphocyte (CD3+CD19+) count correlated with intermediate and impaired response while an elevated monocyte (CD14+CD33+) levels predicted a complete and intermediate (ypT1-4ypN0) response to nCRT/CT. On a tissue level, patients with a complete response displayed a decrease in the amount of infiltrating neutrophils as the immunoscore of CD15+ cells was significantly higher in patients’ biopsies compared to post-nCRT/CT surgical specimen, while in both, patients with complete and intermediate response an increase of natural killer (CD56+) cell density and GranzymeB expression was observed. Finally, no significant correlation was observed between peripheral blood and tissue immune marker expression.
To validate and expand these findings, a continuation of the analysis in an extended patient cohort is necessary. In addition, a detailed insight on the role of peripheral blood T cells and monocytes and their activation status is desirable. Further, in a follow-up trial, soluble activation markers/cytokines should be assayed, further distinguishing activated from resting or exhausted lymphocytes.
Cancer microenvironment is now recognized as a critical regulator of all stages of cancer development. Beside the tumor vasculature and tumor-infiltrating immune cells, other stromal cells such as cancer-associated fibroblasts (CAFs) regulate tumor growth. Fibroblasts are ubiquitous cells in connective tissue, where they shape the extracellular matrix (ECM). Fibroblasts are usually quiescent but get activated when tissue homeostasis is disturbed. Then, activated fibroblasts rebuild the ECM and communicate with local cells to participate in wound repair. These repair properties can go awry when being unchecked, which can lead to fibrosis and subsequently cancer development. CAFs can promote cancer development by fostering tumor cell growth, polarizing immune cells to an immunosuppressive phenotype, and crosslinking collagen to enable tumor cell invasion. Molecular mechanisms of CAF activation, thus, need to be understood to target these cells in tumors. Prostanoid prostaglandin E2 (PGE2) is viewed as a pro-tumor lipid mediator as suggested by studies pharmacologically or genetically targeting the enzymes producing PGE2, such as microsomal PGE synthase-1 (mPGES-1) in tumor models. Similar to CAFs, PGE2 drives tumor cell growth and tumor-associated immune suppression. Therefore, I hypothesized that PGE2 may play a role in CAF activation.
This hypothesis was tested in two mouse models of breast cancer (orthotopic grafting model, and polyoma middle T oncogene transgenic model), besides using isolated mammary gland (MG) fibroblasts in vitro. As expected, given the pro-tumor function of PGE2, knocking out mPGES-1 reduced the growth of oncogene-driven and transplanted mammary tumors. Surprisingly, CAF density was markedly increased when mPGES-1 was depleted. Importantly, despite reduced primary tumor growth, I observed enhanced lung metastasis upon mPGES-1depletion. Using MG-derived fibroblasts in vitro furthermore revealed that treatment with PGE2 reduced a TGFβtriggered CAF-like activation state. Importantly, bioinformatics analysis of a human breast cancer patient dataset revealed a negative correlation of a PGE2 production signature with fibroblast marker genes. In a next step I investigated if the increased CAF infiltrate was connected to the reduced tumor growth upon depletion of PGE2. To unravel this, I first asked through which E prostanoid (EP) receptor PGE2 signals in fibroblasts. MG fibroblasts mainly expressed EP3, and EP3 KO fibroblasts showed a hyper-proliferative and activated phenotype, indicating EP3 as the main PGE2 receptor in MG fibroblasts. Co-injecting of EP3 KO MG fibroblasts and tumor cells in WT mice suppressed tumor growth, whereas co-injection of WT fibroblasts with tumor cell in mPGES-1 KO mice increased tumor growth. These data indicate that PGE2 restricts CAF levels through EP3, which supports tumor growth. Whole transcriptome mRNAsequencing of WT and mPGES-1 KO FACS-sorted CAFs combined with immunohistochemical data suggested a role of p38 mitogen-activated protein kinase (MAPK) in the modulation of fibroblast activation by PGE2.
In summary, I showed in two breast cancer models that mPGES-1 depletion delays breast cancer progression, which is probably driven by the EP3-PGE2 signaling axis in host stroma. PGE2 appears to be a potent anti-fibroblast activation agent in tumors via EP3 and downstream p38 MAPK signaling. This study therefore hits the dogmatic perception of the general pro-tumor nature of PGE2; showing that PGE2 might be a double-edged mediator that can promote tumor growth at the primary site by restricting CAF expansion, which may in turn hinder infiltration of tumor cells to a secondary site.
Cancer therapies have experienced significant advances in recent years. While conventional cytotoxic chemotherapy has long been the cornerstone for the treatment of many tumor entities, uprising immunotherapies have revolutionized the therapeutic landscape. Among them, immune checkpoint inhibitors (ICIs) with their demonstrated increased overall survival rates and response rates in cancer patients are now FDA-approved for metastatic melanoma and multiple other malignancies. Despite their clinical benefit in cancer therapies, ICIs can induce unique autoimmune-like toxicities known as immune-related adverse events (irAEs), which can involve any organ system including the nervous system. Although neurotoxicities are rare complications of ICI therapy they are often severe and can lead to long-term disability or even death if left untreated.
Neurological irAEs exhibit a broad spectrum of clinical presentations affecting the entire nervous system. Diagnosing neurological irAEs is often challenging as symptoms and laboratory findings can be uncharacteristic for common neurological disorders and clinical experience with ICI-mediated toxicities is still limited. In light of expanding clinical indications for ICIs, physicians will encounter ICI-mediated neurotoxicities more frequently. Thus, thorough characterizations of the diverse set of neurological irAEs are essential for optimal patient care, the prevention of severe ICI-mediated complications, and the development of diagnostic and therapeutic algorithms. This work portrays the clinical presentation, management and outcome of neurological irAEs following ICI therapies.
Patients with neurotoxicities related to ICIs who presented at the Yale New Haven Hospital between January 2014 and June 2018 were retrospectively identified from the quality control database. A comprehensive chart review was performed and data regarding patient demographics, medical history, ICI regimen and neurotoxicity were recorded. In total, 18 patients with neurological irAEs following ICI therapy for melanoma, small cell lung cancer, non-small cell lung cancer, and Merkel-cell carcinoma were identified. Neurotoxicities included central nervous system disorders comprising central demyelinating disorder,autoimmune encephalitis predominantly affecting the grey matter, and aseptic meningitis. Peripheral nervous system toxicities included sensorimotor polyneuropathy and myasthenia gravis. Cases of hypophysitis were also recorded. Time to onset of neurological irAEs ranged from 1 to72 weeks with a median of five weeks. In all patients ICIs were held and steroids initiated. Additional immunomodulatory therapies were required in nine patients. Sixteen of 18 patients showed neurological improvement. Fourteen patients had highgrade neurotoxicity (grade 3-4), six of whom deceased due to cancer progression, while none of the low-grade neurotoxicity patients (grade 1-2) died. High-grade neurotoxicity was identified as a negative prognostic marker for overall survival (p = 0.046).
This work shows that neurotoxicities present early-onset, rapidly progressive complications of ICIs with a broad spectrum of clinical phenotypes affecting the central nervous system, peripheral nervous system, and neuroendocrine system. A high index of caution for neurological irAEs is warranted throughout ICI therapy as timely diagnosis and management can reduce morbidity and mortality. Randomized clinical trials are needed to develop standardized diagnostic and therapeutic algorithms of ICI-induced neurotoxicities.
BH3 mimetics are novel anticancer therapeutics that induce apoptosis by targeting anti‐apoptotic BCL‐2 proteins. Highly specific inhibitors of the main anti-apoptotic proteins BCL-2, BCL‐XL and MCL‐1 promise new opportunities for the treatment of AML. However, it is currently unclear which of these anti-apoptotic BCL-2 proteins represents the most promising target in AML. Therefore, we investigated the effect of BH3 mimetics targeting either BCL-2 (ABT-199, S55746), BCL-XL (A-1331852) or MCL-1 (S63845) on eleven AML cell lines. Drug sensitivity screening revealed heterogeneous sensitivity towards the different BH3 mimetics, with the best responses observed upon targeting of MCL-1. Selected cell lines that displayed sensitivity towards the specific BH3 mimetics underwent intrinsic apoptosis, which was characterized by loss of mitochondrial membrane potential, exposure of phosphatidylserine and activation of caspases. Furthermore, S63845 turned out to displace BIMS and NOXA from MCL-1 to induce apoptotic cell death. Importantly, the translational relevance of this study was demonstrated by experiments in primary AML blasts, which displayed similar sensitivity towards BH3 mimetics as the cell lines did. Additionally, experiments with nonmalignant cells could confirm the clinical relevance of the MCL-1 inhibitor. There we could show, that S63845 does not cause cytotoxicity on HPCs at efficacious doses.
In conclusion, our findings reveal that the inhibition of BCL-2 proteins, especially MCL-1, by BH3 mimetics can be a promising strategy in AML treatment.
Cancer is the major cause of death besides cardiovascular disease. Leukaemia represents the most prevalent malignancy in children with a frequency of 30 % and is one of the ten leading types of cancer in adults. Philadelphia Chromosome-positive B-ALL (Ph+ B-ALL) is driven by the cytogenetic aberration of the reciprocal chromosomal translocation t(9;22)(q34;q11) leading to the formation of the Philadelphia chromosome with a BCR-ABL1 fusion gene. This fusion gene encodes a BCR-ABL1 oncoprotein which is characterized by a constitutively enhanced tyrosine kinase activity promoting amplified proliferation, differentiation arrest and resistance to cell death. Ph+ B-ALL is considered the most aggressive ALL subtype with a long-term survival rate in the range of only 30 % despite intensive standard of care including chemotherapy in combination with a tyrosine kinase inhibitor (TKI) followed by allogeneic stem cell transplantation after remission for clinically fit patients.
The efficacy of chemotherapy has long been mainly attributed to tumour cell toxicity while immune modulating effects have been overlooked, especially in light of known immunosuppressive properties. Accumulative evidence, however, emphasizes the ability of chemotherapeutic agents, including TKIs, to normalise or re-educate a dysfunctional tumour microenvironment (TME) resulting in enhanced anti-tumour immunity. One of the underlying mechanisms of immune modulation is the induction of immunogenic cell death (ICD). ICD is an anti-tumour agent-induced cell death modality determined by the capacity to convert cancer cells into anti-cancer vaccines. The induction of ICD relies on the release of damage-associated molecular patterns (DAMPs) from dying tumour cells succumbing to ICD. Translocation of CALR to the cell surface, extracellular secretion of ATP and release of HMGB1 from the nucleus are key hallmarks of ICD that mediate anti-tumour immunity upon binding to antigen presenting cells resulting in a tumour antigen-specific immune response. Besides these molecular determinants, ICD is functionally defined by the inhibition of tumour growth in a vaccination assay in which mice are injected with tumour cells exposed to the potential ICD inducer in-vitro and then re-challenged with live tumour cells of the same cancer type. Both molecular and functional criteria determine the gold standard approach to assess ICD. By increasing the immunogenicity of cancer cells, ICD contributes to the restoration of immunosurveillance as an essential feature of tumour rejection, which is clinically reflected by improved therapeutic efficacy and disease outcome in patients. Therefore, identifying novel ICD inducers is an objective of interest in the context of cancer therapy.
In respect of these considerations, the aim addressed in the present work is the examination of the second-generation TKI Nilotinib for the ability to induce ICD. The thesis is set in the context of the group's research on the role of Gas6/TAM signalling within the TME regarding the pathogenesis of acute leukaemia. In in-vivo experiments of our research group it has been consistently observed that the use of Nilotinib enhances the anti-leukaemic immunity mediated by a deletion of Gas6. Against the background of increasing importance of chemotherapeutic agents as potent modulators of a dysregulated TME, it was hypothesized that Nilotinib may synergize with a Gas6-deficient environment by inducing ICD in Ph+ B-ALL cells.
In growth inhibition and Annexin V/Propidium iodide cell death assays Nilotinib was shown to induce cell death in concentration-dependent manner that occurs bimodally in terms of cell death modality ranging between apoptosis and necrosis. By ICD marker analysis, comprising flow-cytometric detection of CALR exposure, chemoluminescence-based ATP measurement and immunoblotting for HMGB1, it was found that Nilotinib-induced cell death is not accompanied by CALR exposure and ATP secretion, but is associated with the release of HMGB1. In macrophages co-culture experiments with Nilotinib-treated leukaemic cells, no relevant shift in terms of macrophages activation and polarisation was observed in either a juxtacrine or paracrine setup. In consistency with the results obtained in the in-vitro experiments, Nilotinib was not potent to elicit a protective immune response in mice within a vaccination assay.
Conclusively, Nilotinib was identified to not qualify as bona fide ICD inducer. The role of Nilotinib-induced cell death and HMGB1 release are proposed as objective for further investigation concerning the synergistic interplay between Nilotinib and a Gas6-deficient environment. Efforts addressing exploration and optimisation of the immunological potential of chemotherapeutic agents are a promising approach aimed at providing cancer patients with the best possible treatment in future.
Functional roles of COMP and TSP-4 in articular cartilage and their relevance in osteoarthritis
(2020)
Osteoarthritis (OA) is a slowly progressing disease, resulting in the degradation of cartilage and the loss of joint functionality. The cartilage extracellular matrix (ECM) is degraded and undergoes remodelling in OA progression. Chondrocytes start to express degrading proteases but are also reactivated and synthesise ECM proteins. The spectrum of these newly synthesised proteins and their involvement in OA specific processes and cartilage repair is hardly investigated.
Human articular cartilage obtained from OA patients undergoing knee replacement surgery was evaluated according to the OARSI histopathology grading system. Healthy, non-OA cartilage samples were used as controls. The expression and distribution of thrombospondin-4 (TSP-4) and the closely related COMP were analysed on the gene level by PCR and on the protein level by immunohistology and immunoblot assays. The potential of TSP-4 as a diagnostic marker was evaluated by immunoblot assays, using serum samples from OA patients and healthy individuals. The functional role of both proteins was further investigated in in vitro studies using chondrocytes isolated from femoral condyles of healthy pigs. The effect of COMP and TSP-4 on chondrocyte migration and attachment was investigated via transwell and attachment assays, respectively. Moreover, the potential of COMP and TSP-4 to modulate the chondrocyte phenotype by inducing gene expression, ECM protein synthesis and matrix formation was investigated by immunofluorescence staining and qPCR. The activation of cartilage relevant signalling pathways was investigated by immunoblot assays.
These results showed for the first time the presence of TSP-4 in articular cartilage. Its amount dramatically increased in OA compared to healthy cartilage and correlated positively with OA severity. In healthy cartilage TSP-4 was primarily found in the superficial zone while it was wider distributed in the middle and deeper zones of OA cartilage. The amount of specific TSP-4 fragments was increased in sera of OA patients compared to healthy controls, indicating a potential to serve as an OA biomarker. COMP was ubiquitously expressed in healthy cartilage but degraded in early as well as re-expressed in late-stage OA. The overall protein levels between OA severity grades were comparable. Contrary to TSP-4, COMP was localised primarily in the upper zone of OA cartilage, in particular in areas with severe damage. COMP could attract chondrocytes and facilitated their attachment, while TSP-4 did not affect these processes. COMP and TSP 4 were generally weak inducers of gene expression, although both could induce COL2A1 and TSP-4 additionally COL12A1 and ACAN after 6 h. Correlating data were obtained on the protein level: COMP and TSP-4 promoted the synthesis and matrix formation of collagen II, collagen IX, collagen XII and proteoglycans. In parallel, both proteins suppressed chondrocyte hypertrophy and dedifferentiation by reducing collagen X and collagen I. By analysing the effect of COMP and TSP-4 on intracellular signalling, both proteins induced Erk1/2 phosphorylation and TSP-4 could further promote Smad2/3 signalling induced by TGF-β1. None of the two proteins had a direct or modulatory effect on Smad1/5/9 dependent signalling.
In summary, COMP and TSP-4 contribute to ECM maintenance and repair by inducing the expression of essential ECM proteins and suppressing chondrocyte dedifferentiation. These effects might be mediated by Erk1/2 phosphorylation. The presented data demonstrate an important functional role of COMP and TSP-4 in both healthy and OA cartilage and provide a basis for further studies on their potential in clinical applications for OA diagnosis and treatment.
Correct cellular function is ensured by a complex network of proteins and enzymes, regulating protein synthesis and degradation. This protein network, maintaining the so-called protein homeostasis, regulates those processes on multiple levels, producing new or degrading old proteins to cope with changing intra- and extracellular environments. Disturbance of this tightly regulated machinery can have severe effects on the cell and can lead to a variety of pathologies on organism level. Diseases including cancer, neurodegeneration and infections are associated with causative or consequent alterations in protein homeostasis. To understand the pathologies of these diseases, it is therefore critical to examine how perturbations of protein homeostasis affect cellular pathways and physiology. In the recent years, analysis of protein homeostasis networks has resulted in the development of novel therapeutic approaches. However, for many factors it remains unclear how the cell is affected, if they are disturbed. Protein synthesis and degradation represent immediate responses of the cell to changes and need to be studied in the right timeframe, making them difficult to access by common methodology. In this work we developed a new mass spectrometry (MS) based method to study protein synthesis and degradation on a system-wide scale. Multiplexed enhanced protein dynamic (mePROD) MS was developed, overcoming these limitations by special sample mixing and novel data analysis protocols. MePROD thereby enables the measurement of rapid and transient (e.g. minutes) changes in protein synthesis of thousands of proteins. During responses of the cell to stressors (e.g. protein misfolding, oxidation or infection), two major pathways regulate the protein synthesis: the Integrated Stress Response (ISR) and mammalian target of rapamycin (mTOR). Both pathways have been connected with various diseases in the past and are common therapy targets. Although both pathways target protein synthesis in stress responses, the set of targets regulated by these pathways was believed to differ. Through the new mePROD MS method we could measure a comprehensive comparison of both pathways for the first time, revealing comparable system-wide patterns of regulation between the two pathways. This changed the current view on the regulation elicited by these pathways and furthermore represents a useful resource for the whole field of research. We could further develop the mePROD method and decrease MS measurement time needed to obtain an in-depth dataset. Through implementation of logic based instrument methods, it was possible to enhance the number of measured proteins by approximately three-fold within the same measurement time.
The dynamics of protein synthesis and degradation are frequently modulated by pathogens infecting the cell to promote pathogen replication. At the same time, the cell counteracts the infection by modulating protein dynamics as well. To develop useful therapy approaches to fight infections, it therefore is necessary to understand the complex changes within the host cell during infections on a system-wide scale. In 2019, a novel coronavirus spread around the world, causing a world-wide health-crisis. To better understand this novel virus and its infection of the host cell we conducted a study applying the mePROD methodology and classical proteomics to characterize the dynamic changes during the infection course in vitro. We discovered that the infection remodeled a diverse set of host cell pathways (e.g. mRNA splicing, glycolysis, DNA synthesis and protein homeostasis) and thereby showed possible targets for antiviral therapy. By targeted inhibition of these pathways, we could observe that these pathways indeed are necessary for SARS-CoV-2 replication and their inhibition could reduce viral load in the cells. Another experimental approach focused on the dynamic changes of protein modification, namely phosphorylation, after infection with SARS-CoV-2. Here, we could show the very important participation of growth factor signaling pathways in viral proliferation. Both studies together revealed critical pathways that are needed for the viral proliferation and hence are promising candidates for further therapies. Subsequent targeting of these pathways by either already approved drugs (Ribavirin and Sorafenib) or drugs in clinical trials (2-deoxyglucose, Pladienolide-B, NMS-873, Pictilisib, Omipalisib, RO5126766 and Lonafarnib) could block viral replication in vitro and suggests important clinical approaches targeting SARS-COV-2 infection.
Development of treatment strategies of chronic inflammatory disorders relies on on-going progress in drug discovery approaches and related molecular biologics. This study presents a gene reporter-based approach of phenotypic screening for anti-inflammatory compounds in the context of rheumatoid arthritis (RA).
CEBPD gene, used as the target gene for the screening readout, encodes CCAAT/enhancer binding protein delta (C/EBPδ) transcription factor (TF). Structural and regulatory characteristics of CEBPD gene as well as function of C/EBPδ TF in the context of inflammation satisfied assay requirements. C/EBPδ TF acts as a key regula-tor of inflammatory gene transcription in macrophages (Mϕ) and is observed to con-tribute to disease development in both a rodent model of RA and RA patient biopsies.
Despite well-described pro-inflammatory effects of C/EBPδ TF, it functions as a cell context-specific signal integrator showing also an anti-inflammatory activity. Conse-quently, both activation and inhibition of CEBPD alike may display a desired anti-inflammatory effect. The aim of this study was to develop a high-throughput screening assay for
CEBPD-modulating compounds and confirm hit compounds’ anti-inflammatory effects via gene expression analysis.
Generation and characterization of a multi-gene-reporter cassette 1.0 encoding enzy-matic secreted alkaline phosphatase (SEAP) gene reporter was a priority during the assay development. Chemiluminescent SEAP assay demonstrating high assay sensitivi-ty, broad linear range, high reproducibility and repeatability was chosen to monitor activity of the defined CEBPD promoter (CEBPD::SEAP). PMA-differentiated and M1-polarized THP-1-derived Mϕ stably expressing multi-gene-reporter cassette 1.0 were used as the assay’s cellular system. mRNA expression of both reporter CEBPD::SEAP and endogenous CEBPD mirrored each other in response to a LPS and IFN-g-triggered inflammatory stimulus (M1 treatment), even though the defined CEBPD promoter re-gion, utilized in the assay, contained only the most proximal and known regulatory se-quences. SEAP chemiluminescence in the reporter cells´ supernatant reliably correlat-ed with the M1 treatment-induced CEBPD::SEAP gene expression. The final screening protocol was developed for semi-automatic screening in the 384-well format.
In total, 2054 compounds from LOPAC®1280 and ENZO®774 libraries were screened twice
using the enzymatic SEAP readout with subsequent analysis of 18 selected compounds: nine with the highest and nine with the lowest signals, further characterized by qPCR. Gene expression levels of endogenous CEBPD, CEBPD::SEAP reporter as well as, IL-6,
IL-1β, and CCL2 as inflammatory markers were quantified. qPCR assays failed to corre-late to SEAP readout in 15 compounds within three standard deviations (SDs) from sol-vent control: nine low signal and six high signal compounds. Demonstrating both assay sensitivity and specificity, a correlation between qPCR gene expression and SEAP readout was observed for three hit compounds with signals above three SDs: BET inhib-itors (BETi) GSK 1210151A and Ro 11-1464 as well as an HDAC inhibitor (HDACi) vori-nostat. The control compound trichostatin A (TSA) that reproducibly upregulated SEAP readout is also an HDAC inhibitor with a similar structure to vorinostat and was there-fore included in the anti-inflammatory phenotype analysis.
The observed suppression of IL-6, IL-1ß, and CCL2 gene expression by hit compounds suggested their anti-inflammatory effect in THP-1 reporter Mϕ. mRNA expression of
IL-6 and CCL2 was suppressed by HDACi and BETi at both 4 and 24 hours, while BETi reduced IL-1β mRNA expression 24 hour time point. BETi significantly upregulated gene expression of both reporter CEBPD::SEAP and endogenous CEBPD, 4 hours after M1 treatment. At the same time point, HDACi completely abolished the mRNA expres-sion of the endogenous CEBPD, while simultaneously upregulating mRNA expression of the reporter CEBPD::SEAP. The use of the most proximal 300 base pairs region of en-dogenous CEBPD promoter, making the upstream regulatory elements unavailable in the assay, may account for differential expression levels of SEAP and C/EBPδ TF. This observation corroborated the need to include a longer and more extensive CEBPD´s gene regulatory area. Thus, an improved multi-gene-reporter cassette 2.0 was gener-ated to be used on the basis of a bacterial artificial chromosome (BAC) covering CE-BPD´s genomic area of about 200,000 base pairs.
The generated screening assay is flexible, reliable, and sensitive displaying potential for drug discovery and drug repurposing. The pharmacological modulation of CEBPD gene expression, first reported for GSK 1210151A, Ro 11-1464, and vorinostat, contrib-utes to the understanding of inflammatory responses in Mϕ and may have RA thera-peutic applications.
Background: Previous studies have demonstrated that CF (Cystic Fibrosis) prognosis is dependent of three major parameters: FEV1 (Forced Expiratory Pressure in one second), BMI (Body Mass Index) and need of intravenous antibiotic therapy. The CF centres of Frankfurt, Germany, and Moscow, Russia, care for cystic fibrosis patients. We decided to investigate and compare both centers from 1990 to 2015. No comparable study has been published so far.
Method: German patient data was collected from the national cystic fibrosis database “Muko.web”. Missing values were extracted from the Hospital Information System. Russian patient data were taken directly from the medical records in Moscow. In a descriptive statistical analysis with Bias and R Studio the values were compared.
Result: A total of 428 patients from Moscow (217 male, 211 female; 348 (81,3%) were P. aeruginosa positive) and 159 patients from Frankfurt (92 male, 67 female; 137 (86,2%) with P. aeruginosa positive) were compared with regard to P. aeruginosa positivity, BMI, FEV1 and need of intravenous antibiotic therapy. CF patients in Moscow stratified by age groups had lower BMI than CF patients in Frankfurt (age 16-18: p=0,003; age 19-22: p=0,004; age 23-29: p<0,001; age 30-35: p<0,001; age 36-66: p=0,024). In a matching pairs analysis including 100 patients from Frankfurt and 100 patients from Moscow for the year 2015 FEV1 was significantly lower in Moscow patients (p<0,001).
Conclusion: BMI, FEV1 and need of intravenous therapy have significant impact on survival and on quality of life of CF patients. A lower BMI and a lower FEV1 result in a worse survival and determine the prognosis. This study showed a significant difference in prognostic parameters between Frankfurt and Moscow in the crosssectional analysis for the year 2015. A further study should evaluate this difference to show whether this difference will be found over a longer period of time.
Current research on medical biomaterials have shown that the physical and chemical characteristics of biomaterials determine the body inflammatory cellular reaction after their implantation. The aim of this study was to evaluate the individual effects of the physical characteristics over the initial biomaterial-cellular interaction and the inflammatory cellular reaction. For this purpose, an equine-derived collagen hemostatic sponge (E-CHS) was modified by pressing and evaluated using ex vivo, in vitro and in vivo methods.
The E-CHS was pressed by applying constant pressure (6.47± 0.85 N) for 2 min using a sterile stainless-steel cylinder and cut in segments of 1cm2. Subsequently, E-CHS and the pressed equine-derived collagen hemostatic sponge (P-E-CHS) were studied as two independent biomaterials and compared to a control group (CG).
A blood concentrate containing inflammatory cells known as platelet rich fibrin (PRF) was used to mimic the initial biomaterial-cell interaction and to measure the absorption coefficient of the biomaterials to liquid PRF (iPAC). Additionally, the biomaterials were cultivated together with PRF for 3 and 6 days to measure the induction of pro-inflammatory cytokines (TNF-α and IL-8). The results were obtained through enzyme-linked immunosorbent assay (ELISA) and histological methods. PRF cultivated without biomaterials served as the CG. Additionally, the biomaterials were evaluated in vivo using a subcutaneous model in Wistar rats and compared to sham operated animals (CG) representing physiologic wound healing. After 3, 15 and 30 days, the explanted samples were evaluated using histochemical and immunohistochemical (IHC) staining using the following markers: CD68 (pan macrophages), CCR7 (pro-inflammatory macrophages, M1), CD206 (pro-wound healing macrophages, M2) and α-Smooth Muscle Actin (α-SMA; vessel identification).
After the mixture of liquid PRF with both biomaterials for 15 minutes, the ex vivo results showed that E-CHS was penetrated by cells, whereas P-E-CHS was cell-occlusive. Additionally, P-E-CHS induced a higher release of pro-inflammatory cytokines compared to liquid PRF alone (CG) and E-CHS after 3 days (P< 0.05). Although the biomaterial was pressed, the difference of the iPAC value did not show statistical differences. In vivo, the CG induced at day 3 a higher inflammatory response compared to the experimental groups (EG) (P< 0.05). The intergroup comparison showed that P-E-CHS induced a higher presence of macrophages (CD68+/CC7+) compared to E-CHS at day 3 (P< 0.05). Only CD68+/CCR7+ mononuclear cells (MNCs) were observed without multinucleated giant cells (MNGCs). After 15 days, the presence of macrophages (CD68+ P<0.01 /CCR7+ P<0.001 /CD206+ P<0.05) reduced considerably in the CG. On the contrary, the inflammatory response increased in the EGs (CD68+/CCR7+). The intergroup comparison showed that this increment was statistically significant when comparing E-CHS and P-E-CHS to the CG at day 15 (P<0.01 and P< 0.05 respectively). At this time point, a reduced number of MNGCs were observed in the EGs. In the CG no MNGCs were observed. Furthermore, E-CHS showed a faster degradation rate and was fully invaded by cells and vessels formed in its interior region. On the other hand, P-E-CHS remained occlusive to cell penetration and vessels were formed only in the periphery. After 30 days, the cellular reaction shifted to a higher number of M2 macrophages (CD260+) in all groups and a reduced presence of CD68+ and CCR7+ MNCs. Both biomaterials degraded and only small fragments were found in the implantation bed surrounded by MNGCs (CCR7+).
These results are of high clinical relevance and show that changes in biomaterial properties have a significant impact on their interaction with the body. They also serve as insight into the possibility to develop versatile biomaterials with different applications. For example, E-CHs can be applied to support hemostasis in a bleeding alveolar socket and P-E-CHs by being cell occlusive and having a delayed degradation rate can be applied for guided bone and tissue regeneration.
Although immune checkpoint inhibitors such as anti-PD-1 antibodies have shown remarkable clinical success in many different tumor types, the proportion of patients benefiting from this treatment option remains low. Therefore, there is a need to sensitize tumors for immune checkpoint blockade. In this study two approaches were tested, a chemoimmunotherapy approach combining PD-1 checkpoint blockade with doxorubicin (DOX) chemotherapy, and ablation of the sphingosine-1-phosphate (S1P) receptor (S1PR4) based on the following rationale. Chemotherapy was shown to induce immune paralysis which contributes to tumor relapse, while PD-1 signaling was shown to facilitate the acquisition of chemoresistance. Thus, combinatorial chemoimmunotherapy is expected to be beneficial by maintaining or even activating anti-tumor immunity during chemotherapy. S1PR4 is an immune cell specific receptor, whose ablation slowed tumor progression by activating anti-tumor immunity in a mouse model that was previously insensitive to anti-PD-1 monotherapy. This suggested that S1PR4 ablation might pre-activate immunity to sensitize for anti-PD-1 therapy.
To test these combinatorial approaches, two tumor mouse models were employed, namely the MC38 murine adenocarcinoma model as well as the transgenic polyoma middle T oncogene (PyMT) breast cancer model. In the MC38 model, a mild synergistic effect of PD-1 immune checkpoint blockade and S1PR4 ablation was observed, indicated by improved tumor progression and survival as compared to the WT control, and an increased number of tumor-free mice compared to anti-PD-1 therapy alone in WT mice. These observations correlated with an enhanced natural killer (NK) cell infiltrate and increased CXCL9 and CXCL10 production in anti-PD-1 treated S1PR4 KO tumors. As noted before, the PyMT model was largely resistant to anti-PD-1 monotherapy in a therapeutic setting. S1PR4 ablation alone showed significant tumor reduction that was not further enhanced by anti-PD-1 treatment. The same was observed when chemotherapy with DOX was added, where WT tumors relapsed, while S1PR4 KO tumor did not. Addition of anti-PD-1 did only mildly increase tumor control in S1PR4 KO mice, indicating that S1PR4 KO per se very efficiently re-activated anti-tumor immunity. Since S1PR4 KO induces type I 12 interferon (IFN-1) over-production in S1PR4 KO PyMT tumors, a link between high IFN-1 levels and tumor immunity was tested by using mice deficient in the IFN-1 receptor (IFNAR1). Unexpectedly, DOX chemotherapy was most efficient in mice with IFNAR ablation only as compared to WT, S1PR4 KO or S1PR4 and IFNAR1 double KO mice, although deficiency in IFNAR signaling is predominantly regarded as tumor promoting. The underlying mechanisms need to be tested in future studies. Interestingly, chemoimmunotherapy in WT mice prevented tumor relapse to a similar extent than S1PR4 KO and was superior to chemotherapy or immune checkpoint blockade alone. To investigate mechanisms of chemoimmunotherapy success compared to monotherapy, whole transcriptome analysis was used, which identified a set of genes that were upregulated specifically upon chemoimmunotherapy. This gene signature and, more specifically, a condensed four-gene signature predicted favorable survival of human mammary carcinoma patients in the METABRIC cohort.
Moreover, PyMT tumors treated with chemoimmunotherapy contained higher levels of cytotoxic lymphocytes, particularly NK cells. Gene set enrichment analysis and ELISA measurements revealed increased IL-27 production and signaling in PyMT tumors upon chemoimmunotherapy. Moreover, IL-27 improved NK cell cytotoxicity against PyMT cells in vitro. These data supported recent clinical observations indicating a benefit of chemoimmunotherapy compared to monotherapy in breast cancer and suggested potential underlying mechanisms.
Taken together the present work revealed new strategies to reactivate tumor immunity leading to improved chemotherapy response, namely a combination with immune checkpoint blockade and ablation of S1PR4, which activated different lymphocyte compartments within tumors.
The interleukin (IL)-1 family has been described for its numerous involvement in the regulation of inflammatory processes. Certain members are able to induce inflammation, whereas others have the capacity to inhibit inflammation. The newly discovered IL-1 family member IL-38 shows interesting and innovative properties. While most of these cytokines are pro-inflammatory mediators, IL-38 appears to enter the smaller circle of anti-inflammatory mediators. As a pattern, IL-38 appears to suppress IL-17-driven chronic or auto-inflammation by working as receptor antagonist. These properties, as well as its beneficial effects in models of inflammatory and autoimmune diseases suggest the possibility of IL-38-based therapies. Nevertheless, its role in the resolution of acute inflammation, thereby preventing chronic inflammation, remains unclear.
The first part of my thesis elucidated the role of IL-38 in the resolution of inflammation. I found that the complete absence of IL-38 in IL-38 KO mice leads to a delayed resolution of inflammation in the zymosan-induced peritonitis mouse model, compared to WT mice. This was marked by a persistent neutrophilia and a lower production of pro-resolving mediators during the resolution phase, such as TGFβ1 production from macrophages following efferocytosis of apoptotic cells. Reduced TGFβ1 production from macrophages coincided with reduced levels of regulatory T cells (Tregs), which are known to promote the resolution of inflammation. Unexpectedly, the TGFβ1 production capacity of macrophages did not influence the induction of Tregs from naïve T cells. Rather, IL-38 KO mice had an accumulation of Tregs in the thymus compared to WT mice. This was caused by an impairment of CD62L expression at the surface of Tregs, which is required for Tregs migration outside of the thymus. Higher Treg numbers in the thymus correlated with lower level of Tregs in peripheral lymphoid organs. Importantly, CD62L expression at the surface of IL-38 KO Tregs in the thymus was restored by injecting IL-38 i.p. for 24h. These data indicate a potential key function of IL-38 in the regulation of Treg migration, which is triggered in many cases of autoimmunity.
The second part of my thesis was to study the role of IL-38 in experimental autoimmune encephalomyelitis (EAE) development, given that EAE is IL-17-dependent. Unexpectedly, IL-38-deficient mice showed strongly reduced clinical scores and histological markers of EAE. This came with reduced inflammatory cell infiltrates, as well as reduced expression of inflammatory markers in the spinal cord. IL-38 mRNA was detected in the spinal cord, mainly by resident and infiltrated phagocytes, but also by other cells, such as ependymal cells. IL-38 was upregulated upon pro-inflammatory stimulation of bone marrow-derived macrophages, and its presence was necessary for a complete activation of inflammatory macrophages. My data suggest an alternative cell-intrinsic role of IL-38 in macrophages to promote inflammation in the central nervous system.
In the last part of my thesis, I initiated a project on the function of IL-38 in B cell physiology and antibody production, given the fact that IL-38 is expressed by B cells. I generated preliminary data showing that the absence of IL-38 in mice decreased antibody production. Furthermore, I showed that IL-38 is particularly expressed by plasma cells in human tonsils. This project remains open and further studies will be conducted to investigate how IL-38 regulates antibody production, both in physiological and autoimmune settings. Understanding the role of IL-38 in autoantibody production could lead to original and innovative therapy for patients suffering from auto-inflammatory disease.
In summary, the different projects of my thesis provide evidence that the pro-resolving function of IL-38 may be indirectly linked to the retention of Tregs in the thymus. Moreover, a possible intracellular role of IL-38 within macrophages was described showing opposite properties in the regulation of inflammation. This function could be causatively involved in EAE development. However, further studies remain to be done to find the mechanism of action by which IL-38 regulates Tregs egression and how it influences the EAE development. Complete understanding of the IL-38 biology and differentiation between its extra- vs potential intracellular functions could make it a promising therapeutic target for chronic inflammatory or autoimmune diseases.
Reliable and efficient recording of the error-related negativity with a speeded Eriksen Flanker task
(2020)
There is accumulating evidence that the error-related negativity (ERN), an event-related potential elicited after erroneous actions, is altered in different psychiatric disorders and may help to guide treatment options. Thus, the ERN is a promising candidate as a psychiatric biomarker. Basic methodological requirements for a biomarker are standardized and reliable measurements. Additional psychiatry specific requirements are time efficiency and patient-friendliness.
The aim of the present study is to establish ERN acquisition in a reliable, time-efficient and patient-friendly way for use in clinical practice.
Healthy subjects (N=27) performed a modified Eriksen Flanker Task with adaptive reaction time window and only incongruent stimuli that maximizes the number of errors. All participants were tested for mental health by the Mini International Neuropsychiatric Interview (M.I.N.I.). The first N=12 subjects were part of a pilot study and further N=14 subjects were included for analysis (one subject was excluded due to technical problems). In a test-retest design with two sessions separated by 28 days the reliability of the ERN has been assessed. To ensure external validity, we aimed to replicate previously reported correlation patterns of ERN amplitude with (1) number of errors and (2) negative affect. State affect of each subject was measured by the Positive and Negative Affect Schedule. In order to optimize the clinical use of the task, we determined to which extent the task can be shortened while keeping reliability >0.80.
We found excellent reliability of the ERN (intraclass correlation coefficient =0.806-0.947) and replicated specific correlation patterns (ERN amplitude with relative number of errors: r=0.394; p=0.082; ERN amplitude with negative affect: r=-0.583, p=0.014). The task can be shortened to a patient-friendly and clinically feasible length of only 8 minutes keeping reliability >0.80.
To conclude, the present modified task provides reliable and efficient recording of the ERN, facilitating its use as a psychiatric biomarker.
Bipolar disorder (BD) and major depressive disorder (MDD) are severe mood disorders that belong to the most debilitating diseases worldwide. Differentiating both mood disorders often poses a major clinical challenge, leading to frequent misdiagnoses. Objective biomarkers able to differentiate individuals with BD and MDD therefore represent a psychiatric research field of utmost importance. Recent studies have applied resting-state fMRI paradigms and found promising results differentiating both disorders based on the acquired data. However, most of these studies have focused their efforts on acutely depressed patients. Thus, it remains unclear whether the aberrations remain in a symptomless disease state.
The here presented study addresses these issues by evaluating the ability to differentiate both disorders from one another by conducting a between-group comparison of functional brain network connectivity (FNC) obtained from resting-state fMRI data. Data were collected from 20 BD, 15 MDD patients and 30 age- and gender-matched healthy controls (HC). Graph theoretical analyses were applied to detect differences in functional network organization between the groups on a global and regional network level.
Network analysis detected frontal, temporal and subcortical nodes in emotion regulation areas such as the limbic system and associated regions exhibiting significant differences in network integration and segregation in BD compared to MDD patients and HC. Participants with MDD and HC only differed in frontal and insular network centrality.
These results indicate that a significantly altered brain network topology in the limbic system might be a trait marker specific to BD. Brain network analysis in these regions may therefore be used to differentiate euthymic BD not only from HC but also from patients with MDD.
Limb stump pain after amputation, due to sensitized neuromas, is a common condition that can cause a great deal of suffering in affected patients. Treatment is difficult, requiring a multidisciplinary approach that is often unsatisfactory. One treatment used to mitigate pain is electrical stimulation (EStim), administered using several different therapeutic approaches. The research described in this dissertation sought to characterize changes in peripheral nerve morphology, and neuroma formation, following limb amputation, with an eye toward developing better treatment strategies, that intervene before neuromas are fully formed. Another focus of this study was to evaluate the effect EStim has on changes in peripheral nerve morphology, and neuroma formation, following limb amputation.
Right forelimbs of 42 male Sprague Dawley rats were amputated. At 3, 7, 28, 60 and 90 days post amputation (DPA) 6 limb stumps, in each group, were harvested and changes in peripheral nerve morphology, and neuroma formation were measured. In addition, limb stumps of 6 EStim treated, 6 sham-treated (deactivated EStim devices), and 6 non-treated rats were harvested at 28 DPA.
Analysis revealed six distinct morphological characteristics of peripheral nerves during nerve regrowth and neuroma development; 1) normal nerve, 2) degenerating axons, 3) axonal sprouts, 4) unorganized bundles of axons in connective tissue, 5) unorganized axon growth into muscles, and 6) unorganized axon growth into fibrotic tissue (neuroma). At the early stages (3 & 7 DPA), normal nerves could be identified throughout the limb stump tissues and small areas of axonal sprouts were present near the distal tip of the stumps. Signs of degenerating axons were evident from 7 to 90 DPA. From day 28 on, variability of nerve characteristics, with signs of unorganized axon growth into muscle and fibrotic tissue, and neuroma formation, became visible in multiple areas of stump tissue. These pathological features became more evident at 60 and 90 DPA. EStim treated stumps revealed neuroma formation in 1 out of 6 animals, whereas in sham and controls, neuroma formation was seen in 4 out of 6 stumps respectively.
We were able to identify 6 separate histological stages of peripheral nerve regrowth and neuroma formation over 90 days following amputation. Axonal regrowth was observed as early as 3 DPA, and signs of unorganized axonal growth and neuroma formation were evident by 28 DPA. Our observations suggest that EStim-based treatment and/or other prevention strategies might be more effective if administered in the initial dynamic stages of neuroma development.
Role of Orphan G-protein-coupled receptor GPRC5B in smooth muscle contractility and differentiation
(2019)
G protein coupled receptors (GPCRs) are the largest family of cell-surface receptors encoded in the human genome. They mediate the cellular responses to a wide variety of stimuli, ranging from light, odorants, and metabolic cues to hormones, neurotransmitters, and local mediators. Upon ligand binding, the GPCR undergoes conformational changes resulting in the activation of heterotrimeric G-proteins belonging to the families Gs, Gi/o, Gq/11, G12/13, which in turn mediate the downstream signaling. While most of the 360 non-olfactory GPCRs are well studied, approximately 120 GPCRs are still considered "orphan", meaning that their mechanism of activation and biological function is unknown. GPCRs have been functionally described in the regulation of almost all organ systems, and their dysregulation has been implicated in the pathogenesis of a multitude of diseases. In the vascular system, the contractile tone of vessels is crucially regulated by GPCRs. Substances that act through G12/13- and Gq/11-coupled GPCRs are associated with facilitation of contraction, while Gs-coupled GPCRs are usually associated with the induction of relaxation. Furthermore, while Gq/11 pathway activation promotes proliferation and dedifferentiation of vascular smooth muscle cells (VSMC), G12/13 and Gs signaling pathways promote expression of contractile proteins and differentiation.
The functional properties of VSMC depend on the anatomical location, and a recent single-cell expression analysis showed that VSMC from different vascular beds have different patterns of GPCR expression. Interestingly, smooth muscle cells (SMCs) from resistance arteries not only express various GPCRs for known modulators of vascular tone, but also a number of orphan GPCRs. These results suggest a potential role of orphan GPCRs in the modulation of blood pressure. Orphan GPCR GPRC5B was one of the GPCRs enriched in resistance arteries, and this receptor was also upregulated in dedifferentiated aortal SMC. The function of GPRC5B in these types of SMC is currently unknown. In vitro studies suggested that GPRC5B negatively regulates obesity, inflammation, insulin secretion and fibrotic activity, but there are no data available with respect to its function in regulation of vascular tone or other SMC functions.
Our study aimed at the identification of the specific functions of GPRC5B in SMC. To do so, we generated a SMC-specific GPRC5B-deficient mouse line by crossing Gprc5bfl/fl mice with smooth muscle-specific, tamoxifen-inducible Myh11-CreERT2 mice. We found that SMC-specific deletion of GPRC5B did neither affect myogenic tone in pressure myography, nor the response to the contractile agonists in wire myography. In contrast, vessel relaxation in response to prostacyclin analogues cicaprost and iloprost, which act on the prostacyclin receptor IP, were increased. These results suggested a selective improvement of IP receptor signaling. The IP receptor is coupled to Gs protein, it promotes vasorelaxation and acts as a restraint on platelet activation. Using overexpression of IP and GPRC5B in HEK cells, we found that GPRC5B physically interacts with the IP receptor and controls IP trafficking and membrane localization. Furthermore, we found that membrane IP receptor expression was increased in GPRC5B-deficient human aortic SMC and in resistance vessels of SMC-specific GPRC5B. To investigate the importance of increased IP-mediated signaling in SMC in vivo, we measured blood pressure in two mouse models of hypertension. We found that SMC-deletion of Gprc5b resulted in a significant reduction of blood pressure compared with control mice, which suggested that Gprc5b negatively regulated relaxation in hypertensive disease by decreasing IP mediated relaxation. In line with this notion we found that application of the IP antagonist Cay10441 largely abrogated the beneficial effect of GPRC5B inactivation in this hypertension model. Another important function of the IP receptor is the regulation of SMC differentiation, which led us to investigate the differentiation state of GPRC5B-deficient SMC. We found that deletion of GPRC5B enhanced expression of contractile genes and reduced expression of proliferative markers. This improved differentiation was, at least partially, due to increased IP signaling in SMC. Moreover, in a mouse model of atherosclerosis SMC-specific deletion of Gprc5b reduced plaque area and contributed to a more stable fibrous cap by promoting differentiation.
In conclusion, deletion of GPRC5B in SMC significantly improved contractility and differentiation by increasing IP receptor membrane availability and signaling.
Langzeitbeobachtung der Therapie von Hämophilie A-Patienten mit einem humanen Faktor VIII-Konzentrat
(2019)
This doctoral thesis entitled “Long-term surveillance of the therapy of haemophilia A patients with a human plasma-derived factor VIII concentrate” was performed to assess the influence of the chronic long-term therapy with a human plasma-derived factor VIII concentrate in daily clinical practice on the health of haemophilia A patients.
Haemophilia A is a chronic disease, caused by a congenital deficiency of coagulation factor VIII, which requires life-long haemostatic treatment. The severity of bleedings, as the main clinical feature of haemophilia A, is generally correlated with the residual activity of coagulation factor VIII.
Until recently, factor VIII preparations, used to replace the deficient factor VIII, were the only treatment option for haemophilia A. Development of inhibitory antibodies against factor VIII is the most serious complication associated with the use of factor VIII products, rendering the administered factor VIII ineffective.
To date, all novel treatments still rely on some factor VIII replacement therapy. At least in the near future and probably for longer, (concomitant) therapy with factor VIII concentrates will continue to be necessary for treatment of haemophilia A, emphasising the continuous need for efficacy and safety data in terms of pharmacovigilance on factor VIII replacement therapy.
Medicines to treat haemophilia A, are authorised for use, when evidence of its efficacy and safety is limited to data of a small number of investigated patients during short-term observation periods of about six months, and thus have not been systematically assessed in all patient groups until marketing authorisation. Long-term efficacy and safety data from post-marketing surveillance are important to prove that a chronic treatment is efficacious and safe in the real-life setting by monitoring “real-life” patients of all age groups, rather than a carefully selected patient population. Medical and scientific analyses of such long-term data are crucial to detect, understand, and potentially prevent the harm resulting from (new) adverse drug reactions, including those, which only rarely occur and therefore are difficult to detect.
Therefore, data from two prospective surveillance studies investigating real-life therapies with the same human plasma derived factor VIII concentrate were combined and analysed retrospectively. It was hypothesised that the chronic long term therapy with a human plasma-derived factor VIII concentrate in daily clinical practice is effective, safe, and well tolerated with no unexpected adverse effect on the health of haemophilia A patients. It was the aim of this analysis to investigate the influence of the chronic long-term treatment with the factor VIII concentrate on the health of patients with severe as well as nonsevere haemophilia A including all age groups in a real-life setting. In addition, the influence of prophylactic factor VIII treatment or the switch to this regimen on the annual bleeding rate of all haemophilia A patients, and the long-term effects of this regimen on the patients’ annual bleeding rates were investigated.
Starting in 1998 until 2015, data of 1418 patient-years from 198 haemophilia A patients representing all age groups and haemophilia A severities were analysed. This study covered 18 years of documentation time with a mean observation period of more than seven years per patient. It is the longest study of a single factor VIII concentrate conducted so far, investigating the therapy of haemophilia A. The only observed side effects involved low incident factor VIII inhibitor formation in patients at risk (13 % of previously untreated patients, compared with usually about 30 %). Factor VIII inhibitor development was mainly transient, with low titers, and without clinical relevance. Any, even low frequent prophylaxis was found to be significantly better than on demand and had the greatest effect on the annual bleeding rate of patients, irrespective of their age or haemophilia A severity. Patients suffered during continuous prophylaxis from a very low bleeding rate (median 1.3 compared with 31.4 under on demand), down to no bleeding per year. Patients whose regimen changed to continuous prophylaxis benefitted most (median annual bleeding rate 1.1), irrespective of age or haemophilia A severity.
This analysis demonstrates that the chronic long-term therapy with the plasma-derived factor VIII concentrate in daily clinical practice is effective, safe, and well tolerated. Thus, data on efficacy and safety obtained during chronic long-term therapy with the human plasma-derived factor VIII concentrate reaffirm that there is no unexpected adverse effect on the health of haemophilia A patients.
These results support the therapeutic concept of a life-long prophylaxis of haemophilia A patients with a human plasma-derived factor VIII concentrate.
Characterization of SPRTN, the first mammalian metalloprotease that repairs DNA-protein-crosslinks
(2019)
DNA is constantly exposed to various endogenous and exogenous sources causing different kinds of DNA damage. To overcome this threat, cells have evolved various repair mechanisms. Impairments of these repair mechanisms result in diverse diseases. Ruijs-Aalfs syndrome is a monogenic disease characterized by accelerated ageing and carcinogenesis, typical features of impaired DNA repair and was shown to be caused by germline mutations of SPRTN, a newly identified and only partially understood protein. A role of SPRTN in DNA damage response was previously shown and an involvement in translesion synthesis (TLS) proposed. However, later discoveries revealed an essential function of SPRTN, being indispensible for embryonic development of vertebrates and cellular survival, whereby this function is independent of SPRTN’s proposed function in TLS. The essential function of SPRTN was proposed to be contained in its protease domain but remained unclear.
In this study we identify SPRTN as the first mammalian metalloprotease that repairs DNA-protein-crosslinks (DPCs). DPCs represent a specific type of DNA-lesions with bulky protein adducts covalently linked to DNA thereby being highly toxic as they potentially stall replication forks and lead to double strand breaks and genomic instability. DPC-repair remains only partially understood despite their frequent appearance and toxicity. With this study we discover and characterize a new mechanism of DPC-repair in mammalian cells - a proteolytic cleavage of the protein adduct by the metalloprotease SPRTN. Accordingly, a proteolytic activity of SPRTN is demonstrated and s SPRTN-recruitment to DNA upon DPC-induction displayed. Furthermore, SPRTN exhibits degradation of different proteins covalently bound to DNA in form of DPCs, but not of unbound fractions of the same protein substrates. Consequently, mutations of SPRTN’s proteolytic core as well as a mislocalization or depletion of SPRTN result in impaired DPC-repair. The importance of SPRTN-mediated DPC-removal is confirmed by a severely compromised response to DPC-inducing agents for cells with impaired SPRTN function. Additionally to the discovery of SPRTN’s essential function this study further provides an explanation of the molecular mechanism underlying Ruijs-Aalfs syndrome (RJALS), the segmental progeroid syndrome resulting from SPRTN mutation. The effects of the identified clinical mutations on the DPC-repair function of SPRTN are explained and a DPC-accumulation in cells carrying clinical SPRTN-mutation displayed. The obtained data provides sufficient evidence that an impaired DPC-repair is the pathophysiologic cause of RJALS-syndrome, confirming the importance of SPRTN’s newly identified function. In conclusion, SPRTN is the first identified mammalian metalloprotease with a DPC-repairing function and the impairment of SPRTN-mediated DPC-removal is the underlying mechanism of RJALS syndrome.
Durch Implementierung eines effizienten Früherkennungsprogramms ist die Inzidenz des Zervixkarzinoms in Industrienationen seit 2005 auf konstant niedrigem Niveau. Ungeachtet dessen ist das Zervixkarzinom mit deutlich höheren Inzidenzraten und weniger als 50% Gesamtüberleben in den nicht industrialisierten Staaten die vierthäufigste Tumorentität der Frau weltweit.
Zur Behandlung des lokal fortgeschrittenen Zervixkarzinoms (FIGO Stadium IIb bis IVa bzw. Ib2/IIa2 mit mehreren histologischen Risikofaktoren) besteht nach aktueller Leitlinie (Stand 2014) und internationalem Konsens Indikation zur platinhaltigen Radiochemotherapie (RCT), subsequent gefolgt von einer (High Dose-Rate) Brachytherapie (HDR-BT). Unter diesen Umständen beträgt die lokale Kontrolle für Patientinnen mit lokal fortgeschrittenem Tumor zwischen 74% und 85%.
Dennoch stagnieren Gesamtüberleben und das spezifische Überleben bezogen auf verschiedene klinische Endpunkte, sodass die Entwicklung neuer Behandlungsstrategien und Therapieoptionen, insbesondere zur Behandlung rezidivierter und metastasierter Erkrankungsstadien, angezeigt ist. Darüber hinaus spielen im Gegensatz zu anderen Tumorentitäten molekulare Marker sowohl als prädiktive als auch als therapeutische Targets bei der Behandlung des Zervixkarzinoms eine bislang untergeordnete Rolle, während molekular-zielgerichtete Therapien in der modernen Krebstherapie einen immer größeren Stellenwert einnehmen.
Ziel der hier vorliegenden Arbeit ist es, neue Biomarker für das Zervixkarzinom und dessen Ansprechen auf simultane Radiochemotherapie und anschließende Brachytherapie zu identifizieren.
Zu diesem Zweck untersuchten wir in einem Patientenkollektiv von 74 Patientinnen mit histologisch gesichertem Zervixkarzinom (FIGO Ib - IVb) prätherapeutisch gewonnenes Biopsiegewebe. Mittels immunhistochemischer Methoden wurde die Expression von Polo-like Kinase 3 (PLK3) und phosphoT273 Caspase-8 erfasst und quantifiziert. Die Ergebnisse wurden anschließend mit klinischen bzw. histo-pathologischen Charakteristika, einschließlich der p16INK4a Expression und den klinischen Endpunkten lokales progressionsfreies- und Fernmetastasen-freies
Überleben bzw. dem tumorspezifischem und dem Gesamtüberleben nach kurativ intendierter Therapie korreliert.
Hierbei konnte zunächst eine signifikante Korrelation zwischen der PLK3 und pT273 Caspase-8 Expression beobachtet werden (p = 0.009). Darüber hinaus war PLK3 signifikant mit dem N-Status (p = 0.046), dem M-Status (0.026) und dem FIGO-Stadium (p = 0.001) assoziiert, wohingegen die pT273 Caspase8-Expression signifikant mit der Tumorgröße (T-Stadium) korreliert war. Bezogen auf univariate Überlebenszeitanalysen war eine erhöhte PLK3-Expression signifikant mit einer geringeren Rate an Fernmetastasen (DMFS p = 0.009) sowie einem signifikant verlängertem tumorspezifischen und Gesamtüberleben assoziiert (CSS p = 0.001, OS p = 0.003). Vergleichbare Ergebnisse konnten auch für die pT273-Caspase 8 Expression mit einer verringerten Metastasierungsrate (p=0.021) und verbessertem tumorspezifischem (p<0,001) sowie Gesamtüberleben (p=<0.001) gezeigt werden. In den multivariaten Analysen verblieb die pT273-Caspase 8-Expression mit einem signifikant verbesserten Gesamtüberleben (p=0.001).
Zusammenfassend belegen diese Daten erstmals eine signifikante Korrelation zwischen einer erhöhten prä-therapeutischen PLK3 und pT273 Caspase 8- Expression und einem zu favorisierenden klinischen Verlauf nach mit Radiochemotherapie behandeltem Zervixkarzinom.
Acute and chronic inflammation play a pivotal role in various diseases, such as rheumatoid arthritis, atherosclerosis, bacterial as well as viral infections and therefore are an everyday-challenge in clinical practice. In this context, biologically active products of the cyclooxygenases and the prostanoid synthases, e.g. prostaglandins, critically contribute to various aspects of the inflammatory response in almost every tissue of the body. Emerging evidence over the past decades has demonstrated that these mediators are not only responsible for a pro-inflammatory response, but also show anti-inflammatory and pro-resolving properties. The relevance of biologically active lipids in this context is strengthened by the clinical efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs), e.g. Aspirin®, which block the biosynthesis of the mediators via the cyclooxygenase (COX) enzymes. Notably, microsomal prostaglandin E synthase-1 (mPGES-1)-derived prostaglandin E2 (PGE2) is a well-studied, functionally versatile PG, which promotes its effects via specific G protein-coupled receptors (GPCRs). Activation of these receptors elicits an internal signal transduction cascade, including activation of the adenylyl cyclase (AC). Active AC contributes to an elevated intracellular cyclic adenosine monophosphate (cAMP) level, which in turn activates the transcription factor cAMP response element-binding protein (CREB) via phosphorylation.
While the role of PGE2 in the inflammatory context has been well-documented in previous literature, relatively little is known about CREB-dependent transcriptional changes in inflammation. Therefore, the aim of this study was to investigate the effect of mPGES-1-derived PGE2 on CREB-mediated transcriptional changes specifically in murine wild-type (WT) and mPGES-1 knock-out (KO) macrophages in an inflammatory context. To address this issue, bone marrow-derived macrophages (BMDMs) were treated with either the bacterial cell wall component lipopolysaccharide (LPS) in combination with interferon-γ (IFN-γ) or the yeast extract zymosan. To analyze effects on CREB activation we determined protein expression profiles of relevant PGE2-synthesizing enzymes, i.e. COX-2 and mPGES-1, as well as activity of the downstream transcription factor CREB. The activity of mPGES-1 was simultaneously determined by the analysis of the prostanoid kinetics. Under these experimental conditions we showed that COX-2 is strongly induced, and we also observed elevated activated CREB levels in WT as well as in mPGES-1 KO macrophages. Further, both LPS+IFN-γ and zymosan increased expression of mPGES-1 in WT but not in mPGES-1-deficient macrophages. These findings go in hand with largely similar alterations in the PGD2, TXB2, PGF2α profiles in WT and mPGES-1 KO macrophages upon stimulation. Of note, an elevated PGE2 production was also observed in mPGES-1-deficient macrophages at later stages upon inflammatory conditions. Subsequently, potential CREB-regulated targets were identified in macrophages upon inflammatory stimuli after 16 h by chromatin immunoprecipitation (ChIP) followed by Next-Generation-Sequencing (NGS). Surprisingly, despite equal levels of pCREB the characterization of CREB binding sites revealed different targetome profiles between WT and mPGES-1 KO macrophages. Specifically, the fatty acid metabolic processes-associated targets appeared to be selectively lost in mPGES-1-deficient vs. WT macrophages. We further validated one of those targets, i.e. the endoplasmic reticulum lipid raft-associated protein 1 (Erlin1), at the mRNA expression level, which indeed was differentially transcribed in response to different PGE2 synthesizing conditions.
Mechanistically, CREB is a well-characterized phosphorylation-dependent transcription factor in cell survival, proliferation, differentiation, and immune responses. Yet, our understanding of the functions of CREB in inflammation, specifically with respect to its activation by PGE2, is insufficient. Due to its biological relevance in inflammation it clearly requires additional studies to shed light on the details of CREB activation in macrophages to provide possibilities of therapeutic interventions.
The carpal tunnel syndrome (CTS) is a chronic compression of the median nerve in the carpal tunnel, a condition in which the nerve is constricted especially under the flexor retinaculum (FR). The disease predominantly appears between 40 and 83 years of age. Women are significantly more often affected than men. The same applies to overweight people in comparison to normal weight people. Abnormal sensations at night, including paresthesias and dysesthesias, are classical CTS symptoms, predominately involving the middle fingers, later also the thumb. Diagnosis of CTS usually proceeds by motor nerve conduction study (mNCS) and determination of the distal motoric latency (DML). In conformity with electrophysiology, peripheral nerve ultrasonography has also attained an important diagnostic informative value. In principle, there is an open surgical procedure and an endoscopic carpal roof cleavage. The goal of therapy is the complete open division of the flexor retinaculum (FR) in order to relieve the median nerve from compression.
This work examines the morphological alterations of the median nerve at the site of the carpal tunnel after surgical decompression by means of high-resolution neurosonography in the scope of a prospective study. More than 100 patients were examined between October and December 2014 for planned decompressions surgery due to CTS. A total of 81 patients were prospectively included, 5 of which could not take part in the follow-up after six months and were excluded from this evaluation. A medical CTS case history, clinical examination findings, as well as a neurographic result were included. Patients with a relapse operation were not considered in this regard. Apart from a clinical examination and questioning of the patient three and six months after surgery, an electrophysiological examination and a high-resolution sonography of the median nerve were also carried out. Electroneurography and nerve sonography of the median nerve were applied to both hands. A prolonged distal motor latency of the median nerve amounting to 4ms, as well as a slowed nerve conduction velocity below the benchmark value of approx. 45m/s, were classified as pathological findings. In sonography, the largest cross-section area (CSA) of the median nerve was measured by applying transversal slicing to the distal transverse creases of the skin on the palmar surface of the wrist (rasceta) as well as 5cm proximal to the rasceta. The highest CSA values were determined visually. In cases of doubt several transversal slices were made until the highest CSA value could be identified.
The average age at which the disease was contracted amounted to 56.9 years. With one exception, all patients complained of nocturnal brachialgia before surgery (74, 96.2%). As far as neurological symptoms were concerned, 72 patients had paresthesias (93.6%) and 29 patients (37.7%) felt permanent numbness. A thenar atrophy of higher degree was diagnosed in two patients (2.6%). These complaints had improved in the patients surveyed in the scope of postoperative evaluations after three and six months.
Patients with motor deficits had a statistically significantly longer preoperative distal motor latency (10.5 ± 2.8ms vs. 6.5 ± 2.3ms). We observed an improvement of distal motor latency in 98% of the patients three months and six months after surgical decompression, displaying a statistically significant DML decrease from 6.6 ± 2.4ms to 4.8 ± 1.0ms and from 6.6 ± 2.4ms to 4.4 ± 1.0ms, respectively. There was a statistically significant correlation between the decrease of the nerve cross-section area and the decrease of distal motor latency.
At the time of the follow-up examination, three months after surgery, we were able to document a decrease in the CSA value in 80% of the patients. The mean CSA value decreased from 14.7 ± 4.4mm² to 12.4 ± 3.4 mm². Six months after surgical decompression the mean CSA value decreased from 14.3 ± 4.4mm² to 9.6 ± 2.3mm². Patients with a preoperative CSA value of ≥ 12mm² displayed a significantly greater relative reduction of their postoperative CSA value. Concerning all preoperative and postoperative parameters in patients who had undergone either open or endoscopic surgery, none revealed significant differences. Neither could an exploratory analysis (i.e. age, diabetic diseases) reveal any significant correlation between the parameters. Prior to surgery, a flattening of the median nerve or a loss of its fascicular structure (texture) had also been seen to exist in patients, apart from the nerve's larger cross-section area. Nerve sonography is an inexpensive and fast method. It is also extraordinarily reliable in the assessment of the CTS diagnosis and suits the necessary demands. We achieved a good efficiency with our sonographic examinations in the study presented here. New and improved developments show that high-resolution sonography will gain more and more significance in future CTS diagnostics.
The genetic mutation of the coagulation factor VIII (fVIII) results in a defective or missing protein, leading to a malfunctioning blood coagulation. The resulting disease is called hemophilia A. Depending on the severity of the mutation, affected patients experience an increased risk of pathologic bleeding after minor trauma or even sudden bleeding events. Substitution therapies with extrinsic fVIII exist using plasmatic or recombinant fVIII products. Due to an insufficient immune tolerance towards substituted fVIII, about 30 % of patients develop allogenic neutralizing antibodies (inhibitors) against substituted fVIII products. The gold standard of treating inhibitors is the immune tolerance induction (ITI), where patients are given frequent, high doses of fVIII to induce an immune tolerance. ITI therapy fails in about 30 % of patients. Mechanisms of action of ITI are part of research, as insufficient knowledge about mechanisms and prognostic factors complicate treatment. For example, the development of anti-idiotypic antibodies, which occur naturally as a regulatory mechanism of the immune system, are being studied. Such anti-idiotypes have been detected in immunoglobuline preparations and in patients after successful ITI.
Inhibitors interfere with fVIII function in coagulation by binding functional epitopes within fVIII domains. Inhibitors against the A2 and C2 domain are predominantly found, however also the C1 domain has been shown to be highly immunogenic in some patients. The polyclonality of inhibitors aggravates the understanding and treatment of these. The present project therefore focusses on the selection of synthetic anti-idiotypic antibodies to target inhibitors in patients. The phage display method was applied to, for one, isolate anti-idiotypic single chain variable fragments (scFvs) specific against human polyclonal anti-fVIII antibodies and second against two C1 domain-specific inhibitory monoclonal antibodies (mAbs).
In the first project, anti-fVIII antibodies were purified from human plasma to serve as target molecules. A previous project showed that using full plasma as a target did not yield anti-idiotypic antibodies from phage display. For the purification, protein A chromatography and fVIII coupled Affi Gel® chromatography were applied. The isolated antibodies were next used as targets for the selection of anti-idiotypic scFvs. Analysis revealed that none of the selected phages solely bound the anti-fVIII antibody target. Consequently, the test protocol was modified, which resulted in a reduction of unspecific binders. Yet, no target-specific binders were isolated from phage pools. Reason for this may have been the high diversity of the polyclonal antibody target and the limited diversity of the phage libraries.
The aim of the second project, was the selection and characterization of scFvs, that target the paratopes of C1 domain-specific mAbs GMA8011 and LE2E9. From a therapeutic viewpoint, the preparation of an anti-idiotypic antibody pool, tailored to each patient’s inhibitor population, could help neutralize inhibitors in patients. Ultimately, one GMA8011-specific scFv-carrying phage clone (H2C1) and two specifics to LE2E9 (H3G7, H3F10) were isolated. In further experiments, only the GMA8011-specific scFv showed competitive behavior in presence of fVIII, pointing towards an anti-idiotypic binding to the inhibitor paratope. The LE2E9-specific scFvs did not prevent binding of the inhibitor to fVIII. Hence, no anti-idiotypic behavior could be determined. For further characterization, selected scFvs were genetically fused to Fc antibody fragments and recombinantly produced. In this antibody format, all three scFvs showed concentration dependent binding to the target and the isotype control. The binding specificity to the target, observed in phage context, could not be reproduced. Competition experiments with fVIII confirmed that none of the scFvs bound the paratope of their target inhibitor.
The selection of anti-idiotypic scFvs from phage display libraries proves to be effortful. Polyclonal anti-fVIII antibodies purified from hemophilic plasma appear to be unsuitable as a target for phage display, likely due to the high diversity of the target molecules. Furthermore, the preparation of an individualized anti-idiotypic pools for patients by selecting scFvs against single inhibitory mAbs proves to be difficult. The selection of scFvs against anti-C1 inhibitors GMA8011 and LE2E9 produced three promising scFv-carrying phages. However, analysis could not detect anti-idiotypic behavior. Further research with inhibitors, monoclonal and polyclonal, and anti-idiotypic antibodies should be performed to bring better insight into the highly complex paratope-epitope interaction.
The ubiquitin-related SUMO system represents a versatile post-translational modification pathway controlling a variety of cellular signalling networks. In mammalian cells, lysine residues of target proteins can be covalently modified with three SUMO isoforms (SUMO1, SUMO2 and SUMO3) resulting in conjugation of either single SUMO moieties or formation of poly-SUMO chains. Importantly, SUMO modification is a reversible process, where the deconjugation of SUMO from its substrates is mediated by SUMO proteases. In humans, the best-characterized subfamily is the SENP family of SUMO-specific isopeptidases comprised of SENP1-3 and SENP5-7. For undisturbed cellular signalling events, a proper balance of SUMO conjugation and deconjugation is crucial. SENPs fulfil the important function of counteracting SUMOylation. A key question is how the relatively low number of SENPs specifically controls the SUMOylation status of hundreds of cellular proteins.
The aim of this thesis was to uncover the regulation and substrate specificity of distinct SUMO isopeptidases in order to better understand their role in cellular signalling pathways.
In the first part of this work, we investigated the influence of hypoxia on SUMO signalling, in particular on the activity of SENPs. Importantly, we found that the catalytic activity of distinct SENPs (especially SENP1 and SENP3) is strongly but reversibly diminished under low oxygen. As a consequence, the SUMO modification of a specific subset of proteins is changed under hypoxia. We specifically identified proteins being hyperSUMOylated after 24 hours of hypoxia by SUMO1 immunoprecipitation followed by mass spectrometry. We further validated the transcriptional co-repressor BHLHE40 as hypoxic SUMO target and confirmed SENP1 as responsible isopeptidase for deconjugation of SUMOylated BHLHE40. We provide evidence that SUMO conjugation to BHLHE40 enhances its repressive functions on the expression of the metabolic master regulator PGC-1α. Therefore we propose a model where inactivation of SENP1 under hypoxia results in SUMOylated BHLHE40, possibly contributing to metabolic reprogramming under hypoxia.
To get insight into substrate selectivity of SENP family members, in particular SENP3 and SENP6, we choose a proteomic profiling strategy. For the identification of specific SUMO substrates controlled by SENP3, we applied a large-scale IP-MS approach in SENP3 KO and WT cells. The most strongly induced SUMO targets in the absence of SENP3 were key regulators of ribosome maturation. We identified factors involved in the remodelling of both 90S and 60S pre-ribosomes. SENP3 has already been described as being critically involved in maturation of the pre-60S subunit and 28S rRNA processing. Previously described SENP3-regulated master targets in this process are the ribosome maturation factors PELP1 and Las1L. Importantly, both were also identified as the most significantly regulated SENP3 targets in our unbiased proteomic approach. Importantly, however, enhanced SUMOylation was also detected on 90S-associated regulators, such as BMS1. Altogether, these data strengthen the functional link between SENP3 and ribosome biogenesis and point to a role of SENP3 beyond 60S maturation.
In addition to SENP3, we explored the substrate specificity of SENP6, which mainly acts on polymeric SUMO2/3 chains. Applying a proteomic profiling strategy, we were able to identify SENP6-controlled SUMO networks functioning in DNA damage response as well as chromatin organization. We demonstrated that SENP6 reverses polySUMOylation of several subunits of the cohesin complex, thereby regulating the SUMOylation status and chromatin association of this complex. Furthermore, we found a tight interaction of SENP6 with the hPSO4/PRP19 complex, involved in DNA damage response by activation of the ATR-CHK1 signalling cascade. In cells depleted of SENP6, we observe deficient recruitment of the co-activator ATRIP to chromatin which results in diminished CHK1 activation. We therefore illustrate a general role of SENP6 in the control of chromatin-associated protein networks involved in genome integrity and chromatin organization.
Endothelial dysfunction plays an important role in different pathological conditions, but whether endothelial cell death contributes to the development and progression of certain pathological conditions is rather unclear. Here we found that endothelial cells undergo cell death during pathologies such as LPS-induced sepsis and in models of hindlimb, renal and cardiac ischemia-reperfusion injury. Analyses of mice lacking endothelial key cell death regulators such as TAK1, RIPK3 and Caspase 8 gave us insight in the role of endothelial cell death in these pathological models. For example, increased endothelial necroptosis along with basal inflammation in lungs of TAK1ECKO mice affects susceptibility to LPS-induced sepsis and mortality, which correlated with elevated IFN-gamma and MIP-2 serum levels. Furthermore, we found that inhibition of RIPK3-mediated endothelial necroptosis could reduce the susceptibility of TAK1ECKO mice to LPS-induced sepsis and mortality. In ischemia or ischemia-reperfusion models, inhibition of RIPK3-mediated endothelial necroptosis did not reduce injury in the heart after ischemia, nor did it have any effect on organ function post-injury in the kidney or the heart. Inhibition of necroptosis also did not alter vascularization processes in hindlimb post-ischemia. Taken together, endothelial necroptosis contributes to increased sepsis severity and progression whereas inhibition of endothelial necroptosis can ameliorate susceptibility to sepsis in the absence of endothelial TAK1. Inhibition of endothelial necroptosis however does not play an important role during ischemia or ischemia-reperfusion induced organ injury.
Malaria is an environmental disease, influenced not only by physical and biological environmental factors but also by socio-cultural ones. These factors affect each other, and, in turn, cause the disease in endemic areas. Some factors that cause the high morbidity rate associated with the disease include climate change, physical environment that varies geographically, socio-economic circumstances, and human behaviour in the affected areas. Other risk factors include housing conditions and poor sanitation, lack of hygiene practices, and inadequate health services in endemic areas. Efforts to eliminate malaria have been a topic at various public health meetings for decades. However, in Indonesia, malaria continues to be one of the leading causes of morbidity and mortality. The research aimed to analyse and model the critical variables associated with malaria in endemic areas of Indonesia. So, this included relationships between malaria and both socio-demographic variables and physical environments. The research is in three parts, adding value to a model that determines malaria in Indonesia.
This dissertation follows a cross-sectional design survey. The research data in this PhD dissertation is drawn from four sources: routine reporting of malaria from provincial health departments in South Sumatra; the national basic health research data (IDN acronym: Riskesdas); climate data from the Meteorology, Climatology, and Geophysics Climatological Agency (IDN acronym: BMKG); spatial data from Geospatial Information Agency (IDN acronym: BIG). This study takes a holistic approach, integrating the following univariate, bivariate, and multivariable logistic regressions, to establish a modelling determinant of malaria. Additionally, the researchers compared the performance of both Geographically Weighted Regression (GWR) and Ordinary Least Square (OLS). It also used some statistical analysis software tools for data processing, analysis, visualisation, and the development of the model as follows: Statistical Package for the Social Sciences (SPSS), Stata, Aeronautical Reconnaissance Coverage Geographic Information System (ArcGIS) 10.3, and GWR 4.0 version 4.0.90 for Windows.
The prevalence of malaria varied according to the local area, which, in turn, was related to the local physical environment that varied geographically. The determinants for malaria cases varied locally and regionally as well. Rural areas with a high percentage of households keeping livestock/pets showed a higher proportion of malaria prevalence than the national average. Other socio-demographic risk factors included gender, age, occupation, knowledge about healthcare, protection against mosquito bites, and condition of dwellings. This study reveals that the independent variables - "rainfall", "altitude", and "distance from mosquito resting sites in the forest," in global OLS analysis- are significantly associated with malaria cases in South Sumatra, Indonesia.
On the other hand, in the GWR analysis, the determinants of malaria cases at the village level vary geographically. Therefore, it is essential for the decision maker, the government, to acquire a more in-depth understanding of region-specific, ecological factors that influence confirmed malaria cases. The findings lead to the recommendation for developing sustainable regional malaria control programs and incentivising malaria elimination efforts, particularly at the village level. In another setting, the research led to the conclusion that the presence of mid-sized livestock comprised a significant risk factor for contracting malaria in rural Indonesia. The recommendation, especially for the study area, is to employ integrated vector management (IVM), for example, the simultaneous implementation of insecticide-treated bed nets (ITNs) and insecticide-treated livestock (ITL). Other factors such as socio-demographic and use of health care facilities were also crucial as they related to malaria prevalence. Further, the research leads to the recommendation for increased education and increased promotion and utilisation of the health care framework to promote knowledge and awareness of villagers on how to protect themselves from Anopheles bites. Finally, improving information concerning the availability of health care services and access to various health facilities in endemic areas is essential.
The present study aimed to assess the tissue response to the SYMBIOS® resorbable collagen membrane SR, which is derived from bovine Achilles tendon, and compare it to the physiological wound healing of a sham operation as a control.
An ex vivo analysis was performed using injectable platelet-rich fibrin (i-PRF), that is gained by the centrifugation of human venous blood and contains fibrin, leukocytes and platelets, to elucidate the membrane permeability and interactions with human cells and plasma proteins. In the in vivo study, a subcutaneous implantation model was established in Wistar rats to evaluate the cellular reactions for up to 30 days after membrane implantation. Histochemical, immunohistochemical and histomorphometric analyses were performed to assess the cellular inflammatory response, vascularization pattern and cell infiltration capacity.
In the ex vivo study, i-PRF components including fibrin, leukocytes and platelets penetrated the membrane after just 15 minutes. Within the observation period, the cellular reaction in the early phase, which included the first 3 days, produced only mononuclear cells. From 10 to 30 days , the formation of multinucleated giant cells (MNGCs) was induced by the collagen membrane. CD-68 positive cells (macrophages) occurred in a high number on day 3, and the number decreased over time up to day 30. Along with the reduction in the number of CD-68 positive cells, the number of MNGCs increased significantly. The presence of MNGCs was accompanied by significantly increased vascularization within the central region of the membrane, and only mononuclear cells (MNCs) did not produce vascularization. In contrast, the accumulated MNGCs were located on the membrane surface. The control group reflected the physiological process of wound healing, as MNGCs did not form over the 30 day period, and a significantly lower level of vascularization was observed compared with the test group.
This finding showed dynamic changes in the cellular reaction, which indicated a relationship between macrophage fusion and MNGC formation, and vascularization of the collagen membrane is circumstantial evidence of a reaction to a foreign body. However, the collagen membrane was able to maintain its structure and integrity over time, showing no signs of premature breakdown and disintegration due to the specific porosity of its membrane structure.
Therefore, we questioned whether the biomaterial-induced formation of MNGCs should be accepted as a biomaterial-induced cellular reaction that is able to restore vascularization or as an adverse reaction. Therefore, extensive preclinical and clinical studies are needed to investigate the type of MNGCs that form in response to the membrane material studied here.
Cancer is one of the leading causes of death across all countries and its diagnosis still yields fear for the affected patient. Although treatment of cancer has made marvelous progress compared to the agents available thirty years ago, a cure for cancer, however, is still a distant prospect. Modern therapy still is a burden for many patients due to heavy side effects. With the development of agents targeting specific molecular targets on cancer cells, a new field of cancer therapy was opened and a small success story in the history of cancer began.
Aurora kinases represent a relatively new target in cancer therapy. The kinase is a essential part of mitosis and cell cycle progression and its overexpression has been shown to be related to many kinds of malignancies. Allosteric inhibition of a kinase is an increasing pre-clinical approach not yet established in the treatment of patients. In this thesis, we combine allostery with another innovative approach that is drug repurposing. If repurposed, a drug can be permitted to fast track drug admission to clinical trials.
I set up a screening of 1280 FDA approved drugs to identify small molecule compounds that affect the binding of Aurora kinase A and its main physiologic binding partner, TPX2. Further, I characterized the positive hits in vitro for their capabilities to displace TPX2 from Aurora A, to inhibit Aurora kinase activity, to thermally stabilize the protein and performed assays to determine their dissociation constant. Last but not least, I tested the compounds in cells for their effect on the cell viability and cell cycle via flow cytometry. Comparing the hit-compounds with controls I found that ATP-competitive AurA inhibitor MLN 8237 strongly displaces the interaction of Aurora A with TPX2.
Summarized, we identified eight hit compounds allosterically affecting Aurora A, but no compound proved to be active in all assays. Just one compound, PS 731, identified in another screening performed by our group and further characterized in this thesis remains interesting, especially when put in context with recent publications released in the time between the start of experiments for this thesis and its finalization.
How much we trust our own decisions, knowledge or perceptions influences our behavior in many everyday situations. Normally the confidence we have in our decisions is rather accurate, but under certain circumstances the subjective evaluation of a decision and its objective quality can differ heavily. Subjectively over- or underestimating the quality of decisions can lead to disadvantageous behavior. Little is known about how this feeling of confidence about a decision is generated. Is it computed automatically with the decision or does it arise in a different process?
This thesis is based on a publication that contributed to the investigation of this question by comparing the influence of two different forms of spatial attention on decision confidence. Visual spatial attention is a cognitive mechanism that serves to select parts of the visual field, leading to more accurate decisions about the attended items. It can be either voluntarily controlled (endogenous) or reflexively driven by external events (exogenous). In an orientation-matching task participants performed better in both attentional conditions than in a control condition without directed attention. Additionally, we found that only endogenous, but not exogenous attention led the subjects to overestimate the quality of their performance. The possible implications of this “relative overconfidence” were discussed with respect to the theoretical framework of spatial attention and decision confidence. The present findings support the idea that decision confidence is generated in a distinct metacognitive process. Possible ideas for further neurophysiological research are proposed. The thesis concludes with an attempt to integrate the discussion into a broader context of medical research on certain neuropsychiatric symptoms and conditions.
Obesity is considered as a type of chronic inflammation. It enhances the risk of developing cardiovascular disease, diabetes, and some cancers. The key players in the induction of inflammation in adipose tissue are macrophages. However the mechanism of macrophage activation in obese fat tissue is still not fully understood. Elevated level of saturated fatty acids in adipose tissue promotes inflammation and insulin resistance. Exposure of macrophages to saturated fatty acids stimulates pro-inflammatory c-Jun N-terminal kinase (JNK), nuclear factor kappa B (NF-kB) signaling, and production of pro-inflammatory cytokines, such as IL-6, IL-8, IL-1β, and TNFα. Palmitate is a major saturated free fatty acid released by adipocytes. It activates inflammatory pathways through Toll-like receptors (TLR) 2 and 4, provokes endoplasmic reticulum (ER) stress and increases levels of diacylglycerols (DAGs) and ceramides. Saturated fatty acids also affect cellular oxidative metabolism. Thus, mitochondrial fatty acid oxidation reduces ER-stress and expression of inflammatory cytokines in palmitate-treated macrophages. On the other hand mitochondrial reactive oxygen species (ROS) promote palmitate-mediated pro-inflammatory cytokine production. Recently, mitochondrial functions were linked to their morphology. Mitochondrial fission has been reported in β-cells and myocytes in response to high levels of glucose and free fatty acids, and was associated with disruption of mitochondrial functions, increased ROS level, and cell death. The aim of this study was to investigate the role of mitochondrial fragmentation in palmitate-induced inflammation in human macrophages. In our settings fatty acids, independently of their saturation, affected mitochondrial morphology. Mixtures of long chain saturated and unsaturated fatty acids as well as triglyceride-rich lipoprotein lipolysis products promoted mitochondrial fission. Mitochondrial fragmentation in palmitate-treated macrophages revealed a time- and concentration-dependent character, and was reversible upon palmitate removal. This observation, together with unaltered levels of mitochondrial protein and DNA content, and intact mitochondrial respiration, suggested that mitochondria were not damaged and were functionally active. Mechanistically, palmitate-induced mitochondrial fragmentation was not regulated by ER stress or loss of mitochondrial membrane potential. However, inhibition of palmitate incorporation into mitochondrial membrane phospholipids decreased mitochondrial fragmentation. Other approach to prevent mitochondrial fission was the inhibition of dynamin-related protein 1 (DRP1) activity, which drives mitochondrial fission by forming ring- like structures around mitochondria and constricting mitochondrial membranes. Palmitate altered mitochondrial membrane lipid composition and promoted DRP1-oligomerization. The inhibition of palmitate-induced mitochondrial fragmentation enhanced mitochondrial ROS production, c-Jun phosphorylation, and upregulated expression of pro-inflammatory cytokines. Taken together, these results suggest that mitochondrial fragmentation is a protective mechanism attenuating palmitate-induced inflammatory responses. Future experiments will be required to investigate the role of mitochondrial fragmentation in obesity-associated diseases in vivo.
Background: Minimally invasive coronary artery bypass grafting (MICS CABG) has been introduced to abstain from median sternotomy due to related comorbidities. The aim of this study is to report the long term results of three different MICS CABG strategies: Partial lower sternotomy (PLS), totally endoscopic coronary artery bypass grafting (TECAB) and anterolateral thoracotomy (ALT). Moreover we aimed to compare these surgical approaches in terms of quality of pain and pain intensity.
Methods: From 1997 to 2006, 126 patients underwent MICS CABG surgeries in our department through different surgical approaches: 43 PLS, 63 TECAB and 20 ALT. Preoperative characteristics were similar between groups. There were 90 males (71.4%) and 36 (28.6%) females with a mean age of 62±11 years (Range 36 to 90).
Results: There was no in-hospital mortality. Conversion to minithoracotomy was necessary in 2 (1.6%) patients and conversion to sternotomy was performed in 1 (0.8%) patient. Length of hospital stay was comparable in patients who underwent PLS or TECAB, but both groups had significantly shorter hospital stays than ALT patients (p<0.05). Two patients in group ALT developed temporary neurological complications postoperatively, which was significantly higher than that in groups TECAB (n=0) and PLS (n=0) (p<0.05). Mean follow-up was 12.2±2.1 (range 7.2 to 16.1) years with completed in 81.7 % of the patients. There were 17 late deaths. Freedom from graft problems was 87.5%, 86.5% and 94.7%; freedom from percutaneous coronary interventions (PCI) was 78.1%, 82.7% and 68.4% and freedom from Re-CABG was 100%, 96.1% and 94.7% in PLS, TECAB and ALT group, respectively. Pain intensity was similar between all three groups.
Conclusion: MICS CABG can be performed safely and effectively. Short and long-term outcomes of MICS CABG are comparable with those of the conventional CABG. There were no major differences regarding pain intensity between all three groups, although all three minimally invasive techniques have completely different surgical accesses.
Throughout the entire life, new neurons of the granule cell type (GCs) are continu-ously generated in the mammalian hippocampal dentate gyrus (DG). As a part of the limbic system, the hippocampus is concerned with spatial and declarative memory for-mation. Increasing evidence exists, that adult born granule cells (ABGCs) play an im-portant role in this process. An especially critical period, when these ABGCs are 4-6 weeks old, has come into the focus of research. It is during this specific time-span that the ABGCs express enhanced excitability and synaptic plasticity as well as a lowered threshold for the induction of long term potentiation (LTP), a mechanism associated to learning and memory formation.
This study investigates the time course and dynamics of synaptic integration in ABGCs and mature GCs together with which differences exist between them at various cell ages. Furthermore, spine plasticity following high frequency stimulation (HFS) is analysed focusing on a critical phase of enhanced excitability in 4-5 week old ABGCs.
In this thesis, two approaches at studying the synaptic integration and structural plas-ticity of ABGCs in rats were investigated. This work was performed on fixed brain ma-terial that was provided by two laboratories that performed the in vivo labelling, stimu-lation procedures and brain fixation. In the first project, 6, 12 and 35 weeks old XdU-labelled ABGCs were studied. Adult rats were exposed to an enriched environment and received unilateral intrahippocampal delta burst stimulation (DBS) and LTP induction. The ABGCs and a control population of mature GCs were immunohistologically ana-lysed for Egr1 (early growth response 1) expression. Egr1 is an immediate early gene (IEG), expressed after LTP induction and marks neuronal excitation.
It was found, that unilateral stimulation of the perforant path of the hippocampus re-sults in an increase of Egr1 expression in ABGCs of both hemispheres. It could be shown that the enhanced expression intensity of Egr1 in ABGCs is not a usual state of young GCs but a reaction to DBS. ABGCs from unstimulated control animals and mature GCs expressed lower levels of Egr1. Interestingly, the stimulation induced a similar degree of Egr1 expression intensity in all ABGC age groups. Furthermore, it was found that young ABGC from the infrapyramidal dentate gyrus (DG) express a higher excita-bility than those from the suprapyramidal DG.
In the second project, fixed brain sections were analysed. They stemmed from rat brains containing 28 and 35 day old ABGC that had been transfected with intrahippo-campal RV-GFP (retroviral-green fluorescent protein) injections and had received uni-lateral high frequency stimulation of the medial perforant path in vivo. Nuclear Egr1 expression intensity was analysed in a cell specific manner. Dendritic spine size was measured in the inner-, middle- and outer molecular layer (IML, MML, OML). It was found that in ABGC, stimulation induced Egr1 expression increase is lower than in ma-ture GC. Following HFS, a significant homosynaptic spine enlargement was observed in the MML indicating homosynaptic LTP, while heterosynaptic spine shrinkage was found in the adjacent IML and OML. The latter corresponds to heterosynaptic long term depression (LTD). Homosynaptic plasticity describes an input-specific potentiation of synapses that received direct activation. The weakening of synapses not stimulated dur-ing homosynaptic potentiation is oppositely coined heterosynaptic plasticity1.
A positive correlation between an increase in nuclear Egr1 expression intensity and spine enlargement due to homosynaptic plasticity induced by HFS could be shown. Concomitant heterosynaptic plasticity, as indicated by spine shrinkage was observed. Spine shrinkage in the IML and OML showed a negative correlation to a decrease in Egr1 intensity.
Taken together, the results provide detailed information on the gradual integration of ABGC with ongoing maturation. Cell specific proof for homo- and heterosynaptic plas-ticity following HFS was found in the critical period of synaptic integration of ABGCs.
Glioblastoma multiforme accounts for more than 80% of all malignant gliomas in adults and a minor fraction of new annual cases occurs in children. In the last decades, research shed light onto the molecular patterns underlying human malignancies which resulted in a better understanding of the disease and finally an improved long term survival for cancer patients. However, malignancies of the central nervous system and especially glioblastomas are still related to poor outcomes with median survivals of less than 6 months despite extensive surgery, chemotherapy and radiation. Hence, a better understanding of the molecular mechanism driving and sustaining cancerous mutations in glioblastomas is crucial for the development of targeted therapies. Apoptosis, a form of programmed cell death, is an important feature of eukaryotic cells and crucial for the maintenance of multicellular homeostasis. Because apoptosis is a highly complex and tightly regulated signaling pathway, resisting apoptotic stimuli and avoiding cell death is a hallmark of the cancerous transformation of cells. Hence, targeting molecular structures to reestablish apoptotic signaling in tumor cells is a promising approach for the treatment of malignancies. Smac mimetics are a group of small molecular protein inhibitors that structurally derive from an intracellular protein termed Smac and selectively block Inhibitor of apoptosis (IAP) proteins, which are often aberrantly expressed in cancer. Several studies confirmed the antitumoral effects of Smac mimetics in different human malignancies, including glioblastoma, and give rationales for the development of potent Smac mimetics and Smac mimetic-based combination protocols. This study investigates the antitumoral activity of the bivalent Smac mimetic BV6 in combination with Interferon α. Latter is a well characterized cytokine with an essential role in immunity, cell differentiation and apoptosis. This study further aims to address the molecular mechanisms underlying the antitumoral activity of the combination treatment by using well established molecular cell death assays, flow cytometry, western blot analysis, genetic approaches and selective pharmacological inhibition. Since different Smac mimetics and Smac mimetic-based combination therapies are currently under clinical evaluations, findings of this study may have broad implications for the application of Smac mimetics as clinical cancer therapeutics.
After entorhinal deafferentiation of the hippocampal dentate gyrus a reinnervation of the denervated neurons by axon collaterals can be observed. This process takes place in a matter of weeks. However, the overall functional effect on the hippocampal network is still unclear.
In an effort to investigate this effect of axonal sprouting on the neuronal network of the dentate gyrus we compared the electrophysiological response of the dentate gyrus after electric stimulation in wild-type mice (WT mice) with a normal post-lesion sprouting, with genetically modified mice with an overexpression of the growth-protein CAP23 (cytoskeleton-associated protein 23). CAP23 overexpressing mice (CAP23tg mice) are known to have an enhanced axonal growth and sprouting after lesion.
The mice (both the WT as well as the CAP23tg mice) were deeply anesthetized and a lesion of the perforant path was induced stereotactically with a wire knife. After that the mice were permitted to survive for 4-6 weeks for partial reinnervation of the dentate gyrus before they were again operated and evoked potentials were measured (extracellular recordings of evoked potentials in the dentate gyrus). Non-lesioned litter-mate mice were taken as reference. The sprouting and the correct position of the electrodes was confirmed histologically.
For electrophysiological investigation we assessed laminar profiles and calculated a current-source density (CSD). In lesioned CAP23tg mice compared to lesioned WT mice this CSD-analysis revealed a significant enhancement of the current sink in the area of deafferentiation (outer molecular layer) and a significant excitation in the granule-cell layer.
Our results show that axonal sprouting seems to enhance the excitability of granule-cells. Thus, even if an enhanced axonal sprouting might accelerate the reinnervation of denervated dendrites after lesion, but it also leads to posttraumatic hyperexcitability of the neuronal network. In a therapeutic approach of fascilitating axonal sprouting this hyperexcitability has to be taken into consideration.
The small leucine-rich proteoglycan biglycan (Bgn) is a part of the extracellular matrix providing structure and enhancing fibril stability. In its soluble form, biglycan is able to bind and signal via the innate immune receptors Toll-like receptor (TLR) 2 and 4, thereby activating MAP-kinases and the NF-κB pathway. In macrophages soluble biglycan induces the secretion of several cytokines and chemokines, including TNF-α, CCL2, CXCL5 and CXCL13. A unique feature of biglycan is its ability to stimulate the secretion of mature IL-1β. By orchestrating TLR2 and 4 with the purinergic P2X4 and P2X7 receptor signalling biglycan triggers the activation of the NLRP3/ASC inflammasome, which in turn activates caspase-1 to cleave pro-IL-1β to mature IL-1β. Furthermore, in several inflammatory diseases an upregulated biglycan expression is found. Enhanced levels of biglycan could be measured in plasma and inflamed tissue. In mouse models of sepsis, lupus nephritis and renal ischemic reperfusion injury, biglycan-deficiency improved the disease outcome. Overexpression of soluble biglycan on the other hand increased immune cell infiltration into the kidney by inducing cytokine and chemokine expression in a TLR2/4-dependent manner. These studies emphasise its importance in inflammatory processes, especially in the kidney. Furthermore, the pro-inflammatory effects on macrophages and diseases established biglycan as a danger signalling molecule, yet its role as a soluble molecule in plasma was not further investigated.
Although an increase of soluble biglycan in the circulation could be seen in several inflammatory diseases, the source is not fully unravelled. Previously it could be shown that macrophages and dendritic cells secrete soluble biglycan after stimulation with IL-6 and TGF-β1. However, since these cell are resident in organs and do not circulate in the blood stream their contribution to soluble biglycan levels in plasma is likely minor. Therefore, monocytes as precursor of both macrophages and dendritic cells were investigated as a possible source of circulating biglycan. Analysis of blood from septic patients revealed elevated soluble biglycan levels as well as an increased number of monocytes. Isolated monocytes from healthy volunteers incubated with the inflammatory cytokines IL-1β, IL-6 and TGF-β1 displayed increased biglycan mRNA expression and secretion of soluble biglycan into the supernatant, revealing monocytes as a producer of soluble biglycan in blood. Therefore this work was directed to further investigate the influence of soluble biglycan on circulating monocytes, with regard to sepsis.
Monocytes can be classified into three subtypes, while the classical monocytes express CD14 (CD14++CD16low), intermediate monocytes express both CD14 and CD16 (CD14++CD16+) and non-classical monocytes express mainly CD16 (CD14lowCD16++). The intermediate and non-classical monocytes make up about 10 % of all monocytes and are referred to as CD16-positive subtypes. The CD16-positive monocytes express higher levels of TNF-α and IL-1β upon stimulation and display different migration behaviour. In most inflammatory diseases an expansion of CD16-positive monocytes is observed, especially an increased number of intermediate monocytes frequently correlate with disease severity and mortality. Since septic patients had increased circulating biglycan levels and augmented CD16-positive monocytes, a possible correlation between these two parameters was investigated. Using FACS analysis of biglycan-stimulated monocytes from healthy donors revealed a significant shift from classical to intermediate and non-classical monocytes. This shift was mediated by increased expression of CD14 and CD16 on mRNA and protein levels upon biglycan treatment. Furthermore, biglycan induced the mRNA expression of the adhesion molecules ICAM-1, VCAM-1 and ELAM-1 in CD14-positive monocytes. Four hours after biglycan stimulation an increased ICAM-1 protein expression on the cell surface of classical and intermediate monocytes was observed. Additionally, biglycan-treated CD14-positive monocytes rolled and attached to pre-stimulated endothelial cells to a greater extent compared to untreated monocytes. This demonstrates that biglycan not only triggers the expression of CD14 and CD16 but also induces a functional shift of monocytes. ...